Document:

License Agreement (ReGenX Biosciences)

 EXHIBIT 10.15 
  

					
		  		  	 *  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 LICENSE AGREEMENT 

This LICENSE AGREEMENT (“Agreement”) is entered into as of July 9th, 2013 (“Effective Date”) by and
between ReGenX Biosciences, LLC (formerly known as ReGenX, LLC), a limited liability company organized under the laws of the State of Delaware, with offices at 750 17th Street, NW, Suite 1100, Washington, DC 20006 (“Licensor”), and
Audentes Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, with offices at [*] San Francisco, California, 94115 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a
“Party” and collectively as the “Parties.” 
 WHEREAS, Licensor has rights under certain Licensed Patents
(as defined herein) pertaining to adeno-associated virus serotype 8 and 9; and 
 WHEREAS, Licensee desires to obtain an exclusive license
under the Licensed Patents under the terms set forth herein; 
 NOW, THEREFORE, in consideration of the promises and covenants contained m
this Agreement, and intending to be legally bound, the Parties hereby agree as follows: 
 ARTICLE 1: DEFINITIONS 

1.1 “AAV8” means (a) the recombinant adeno-associated virus serotype 8 vector with the specified sequence set forth in
GenBank [*] and (b) any recombinant adeno-associated virus derivatives of such serotype 8 vector that are covered by the claims of the Licensed AAV8 Patents. 

1.2 “AAV9” means (a) recombinant adeno-associated virus serotype 9 vector with the specified sequence set forth in
GenBank [*] and (b) any recombinant adeno-associated virus derivatives of such serotype 9 vector that are covered by the claims of the Licensed AAV9 Patents. 

1.3 “Affiliate” means any legal entity directly or indirectly controlling, controlled by, or under common control with another
entity. For purposes of this Agreement, “control” means the direct or indirect ownership of more than 50% of the outstanding voting securities of a legal entity, or the right to receive more than 50% of the profits or earnings of a legal
entity, or the right to control the policy decisions of a legal entity. 
 1.4 “Calendar Quarter” means each three-month
period or any portion thereof, beginning on January 1, April 1, July 1, and October 1. 
 *Confidential
Treatment Requested. 

 1.5 “Confidential Information” means and includes all technical information,
inventions, developments, discoveries, software, know-how, methods, techniques, formulae, animate and inanimate materials, data, processes, finances, business operations or affairs, and other proprietary ideas, whether or not patentable or
copyrightable, of either Party that are (a) marked or otherwise identified as confidential or proprietary at the time of disclosure in writing; or (b) if disclosed orally, visually, or in another non-written form, identified as
confidential at the time of disclosure and summarized in reasonable detail in writing as to its general content within 30 days after original disclosure. The Parties acknowledge that (i) the terms and conditions of this Agreement will be deemed
the Confidential Information of both Parties and (ii) the records and reports referred to Section 3.6 of this Agreement will be deemed the Confidential Information of Licensee, regardless of whether such information is marked or identified
as confidential. In addition, information provided to Licensee pursuant to the provisions of Section 7.1 will be deemed the Confidential Information of Licensor, regardless of whether such information is marked or identified as confidential.
Notwithstanding the foregoing, Confidential Information will not include the following, in each case, to the extent evidenced by competent written proof of the Receiving Party: 

1.5.1 information that was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure
by the Disclosing Party; 
 1.5.2 information that was generally available to the public or otherwise part of the public domain at the time
of its disclosure to the Receiving Party; 
 1.5.3 information that became generally available to the public or otherwise part of the public
domain after its disclosure, other than through any act or omission of the Receiving Party in breach of this Agreement; 
 1.5.4 information
that is independently discovered or developed by the Receiving Party without the use of Confidential Information of the Disclosing Party; or 

1.5.5 information that was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no
obligation to the Disclosing Party not to disclose such information to others. 
 1.6 “Disclosing Party” has the meaning set
forth in Section 5.1. 
 1.7 “Domain Antibody” [*] 

1.8 “FDA” means the United States Food and Drug Administration, or a successor agency in the United States with
responsibilities comparable to those of the United States Food and Drug Administration. 
 1.9 “Field” means, collectively,
the XLMTM Field and the Pompe Field. 
 1.10 “GSK Agreement” means that certain License Agreement entered into between
Licensor and SmithKline Beecham Corporation, effective on March 6, 2009, as amended by that certain Amendment to License Agreement dated April 15, 2009, and as amended from time to time. 

  

					
		  	2	  	*Confidential Treatment Requested.

 1.11 “Licensed AA V8 Patents” means (a) all United States patents and
patent applications listed in part 1 of Exhibit A and (b) any re-examination certificates thereof, and their foreign counterparts and extensions, continuations, divisionals, and re-issue applications. 

1.12 “Licensed AAV9 Patents” means (a) all United States patents and patent applications listed in part 2 of Exhibit
A and (b) any re-examination certificates thereof, and their foreign counterparts and extensions, continuations, divisionals, and re-issue applications. 

1.13 “Licensed Patents” means, collectively, (a) the Licensed AAV8 Patents and the Licensed AAV9 Patents and (b) any
additional claims of patents and patent applications as required pursuant to Section 8.1.5. 
 1.14 “Licensed Product”
means (a) any AAV8 or AAV9 product that is made, made for, used, sold, offered for sale, or imported by Licensee, its Affiliates and any of its or their Sublicensees, the manufacture, use, sale, offer for sale, or import of which product, in
the absence of the license granted pursuant to this Agreement, would infringe or is covered by at least one Valid Claim in the country of manufacture, use, sale, offer for sale, or import, including products manufactured by a process that would
infringe at least one Valid Claim in the country of manufacture, use, sale, offer for sale, or import; or (b) any service with respect to the administration of AAV8 or AAV9 to patients that, in the absence of the licenses granted pursuant to
this Agreement, would infringe at least one Valid Claim of the Licensed Patents in the country of sale. 
 1.15 “NDA” means
a New Drug Application filed with the FDA as described in 21 C.F.R. § 314, a Biological License Application (BLA) pursuant to 21 C.F.R. § 601.2, or any equivalent or any corresponding application for regulatory approval in any country or
regulatory jurisdiction other than the United States. 
 1.16 “Net Sales” means the gross receipts from sales or other
disposition of a Licensed Product (including fees for services within the definition of “Licensed Product”) by Licensee and/or its Affiliates and/or any Sublicensees to Third Parties less the following deductions that are directly
attributable to a sale, specifically and separately identified on an invoice or other documentation and actually borne by Licensee, its Affiliates, or any Sublicensees: [*] In the event consideration other than cash is paid to Licensee, its
Affiliates, or any Sublicensees, for purposes of determining Net Sales, the Parties shall use the cash consideration that Licensee, its Affiliates, or any Sublicensees would realize from an unrelated buyer in an arm’s length sale of an
identical item sold in the same quantity and at the time and place of the transaction, as determined jointly by Licensor and Licensee based on transactions of a similar type and standard industry practice, if any. 

1.17 “Penn Agreement” means that certain License Agreement entered into between Licensor and The Trustees of the University of
Pennsylvania, effective on February 24, 2009, as amended by that letter agreement dated March 6, 2009, and as amended from time to time. 

1.18 “Phase 3 Clinical Trial” means a pivotal clinical trial in humans performed to gain evidence with statistical
significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA
and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.2l (c) or the corresponding regulation in jurisdictions other than the United States. 

  

					
		  	3	  	*Confidential Treatment Requested.

 1.19 “Pompe Field” means the treatment of Pompe Disease (GAA deficiency) in
humans by in vivo gene therapy in humans using AAV8 or AAV9. 
 1.20 “Prosecute” means preparation, filing, and prosecuting
patent applications and maintaining patents. 
 1.21 “Receiving Party” has the meaning set forth in Section 5.1. 

1.22 “Retained Rights” has the meaning set forth in Section 2.2. 

1.23 “Sublicensee” means any Third Party or Affiliate to whom Licensee grants a sublicense of some or all of the rights
granted to Licensee under this Agreement as permitted by this Agreement. 
 1.24 “Third Party” means any person or entity
other than a Party to this Agreement or Affiliates of a Party to this Agreement. 
 1.25 “Valid Claim” means a claim of an
issued and unexpired patent (including any patent claim the term of which is extended by any extension, supplementary protection certificate, patent term restoration, or the like) or a claim of a pending patent application included within the
Licensed Patents, which has not lapsed, been abandoned, been held revoked, or been deemed unenforceable or invalid by a non-appealable decision or an appealable decision from which no appeal was taken within the time allowed for such appeal of a
court or other governmental agency of competent jurisdiction. 
 1.26 “XLMTM Field” means the treatment of X-linked
myotubular myopathy (XLMTM) in humans by in vivo gene therapy in humans using AAV8 or AAV9. 
 ARTICLE 2: LICENSE
GRANT 
 2.1 License Grant. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee an
exclusive, sublicensable (as provided in Section 2.4 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license, under the Licensed Patents to make, have made, use, import, sell, and offer for sale
Licensed Products solely in the Field, including, for the avoidance of doubt, the right to conduct research and development (including by conducting clinical trials in humans and/or animal studies). 

2.2 Retained Rights. Except for the rights and licenses specified in Section 2.1 or as provided in Section 8.1.5, no license
or other rights are granted to Licensee under any intellectual property of Licensor, whether by implication, estoppel, or otherwise, whether any such intellectual property dominates or is dominated by the Licensed Patents. Notwithstanding anything
to the contrary this Agreement, Licensor may use and permit others to use the Licensed Patents for any research, development, commercial, or other purposes outside of the Field. Without limiting the foregoing, Licensee acknowledges and agrees to the
following rights retained by Licensor and its direct and indirect licensors (individually and collectively, the “Retained Rights”), whether inside or outside the Field: 

  
 4 

 2.2.1 Notwithstanding anything in this Agreement to the contrary, the rights and licenses granted
in Section 2.1 shall not include any right (and Licensor and its direct and indirect licensors retain the exclusive (even as to Licensee), fully sublicensable right) under the Licensed Patents to make, have made, use, sell, offer to sell, and
import Domain Antibodies that are expressed by an adeno-associated vector, including AAV8 and/or AAV9. 
 2.2.2 Notwithstanding anything in
this Agreement to the contrary, Licensor and its direct and indirect licensors retain the following rights with respect to the Licensed Patents: 

(a) A non-exclusive, sublicensable right under the Licensed Patents to make, have made, use, sell, offer to sell, and import products that
deliver RNA interference and antisense drugs using an adeno-associated vector, including AAV8 and/or AAV9; and 
 (b) A non-exclusive right
for Licensor’s direct and indirect licensors (which right is sublicensable by such licensors) to use the Licensed Patents for non-commercial research purposes and to use the Licensed Patents for such licensors’ discovery research efforts
with non-profit organizations and collaborators. 
 2.2.3 Notwithstanding anything in this Agreement to the contrary, the rights and licenses
granted in Section 2.1 shall not include any right (and Licensor retains the exclusive (even as to Licensee), fully sublicensable right) under the Licensed Patents: 

(a) to conduct commercial reagent and services businesses, which includes the right to make, have made, use, sell, offer to sell, or import
research reagents, including any viral vector construct (provided that, for clarity, such rights retained by Licensor shall not include the right to conduct clinical trials in humans in the Field); and 

(b) to use the Licensed Patents to provide services to any Third Parties; provided that Licensee’s license under Section 2.1 does
include the right to provide the service of the administration of Licensed Products to patients. 
 2.2.4 Notwithstanding anything in this
Agreement to the contrary, Licensor retains the fully sublicensable right under the Licensed Patents to grant non-exclusive research and development licenses to Affiliates and Third Parties; provided that such development rights granted by Licensor
shall not include the right to conduct clinical trials in humans in the Field or any rights to sell products in the Field. 
 2.2.5
Notwithstanding anything to the contrary in this Agreement, the University of Pennsylvania may use and permit other non-profit organizations or other non-commercial entities to use the Licensed Patents for educational, research, and other
non-commercial purposes. 
 2.3 Government Rights. Licensee acknowledges that the United States government retains certain rights in
intellectual property funded in whole or part under any contract, grant, or similar agreement with a federal agency. The license grant hereunder is expressly subject to all applicable United States government rights, including any applicable
requirement that products resulting from such intellectual property sold in the United States must be substantially manufactured in the United States. 

  
 5 

 2.4 Sublicensing. 

2.4.1 The license granted pursuant to Section 2.1 is sublicensable by Licensee to any Affiliates or Third Parties; provided that any such
sublicense must comply with the provisions of this Section 2.4 (including Section 2.4.2). 
 2.4.2 The right to sublicense granted
to Licensee under this Agreement is subject to the following conditions: 
 (a) Licensee may only grant sublicenses [*] pursuant to a
written sublicense agreement with the Sublicensee. Licensor must receive written notice as soon as practicable following execution of any such sublicenses. 

(b) In each sublicense agreement, the Sublicensee must be required to comply with the terms and conditions of this Agreement to the same
extent as Licensee has agreed and must acknowledge that Licensor is an express third party beneficiary of such terms and conditions under such sublicense agreement. 

(c) The official language of any sublicense agreement shall be English. 

(d) Within [*] after entering into a sublicense, Licensor must receive a copy of the sublicense written in the English language for
Licensor’s records and to share with Licensor’s direct and indirect licensors. The copy of the sublicense may be redacted to exclude confidential information of the applicable Sublicensee, but such copy shall not be redacted to the extent
that it impairs Licensor’s (or any of its direct or indirect licensors’) ability to ensure compliance with this Agreement; provided that, if any of Licensor’s direct or indirect licensors require a complete, unredacted copy of the
sublicense, Licensee shall provide such complete, unredacted copy. 
 (e) Licensee’s execution of a sublicense agreement will not
relieve Licensee of any of its obligations under this Agreement. Licensee is and shall remain [*] to Licensor for all of Licensee’s duties and obligations contained in this Agreement and for any act or omission of an Affiliate or Sublicensee
that would be a breach of this Agreement if performed or omitted by Licensee, and Licensee will be deemed to be in breach of this Agreement as a result of such act or omission. 

2.5 Improvements. 
 2.5.1
Licensee hereby grants to Licensor a non-exclusive, worldwide, royalty-free, transferable, sublicensable, irrevocable, perpetual license (a) to use any Licensed Back Improvements (and any intellectual property rights with respect thereto)
consummate in scope to the Retained Rights and (b) to practice the Licensed Back Improvements (and any intellectual property rights with respect thereto) in connection with AAV8 and AAV9 outside the Field, 

  

					
		  	6	  	*Confidential Treatment Requested.

 
including the right to research, develop, make, have made, use, offer for sale, and sell products and services outside the Field. For purposes of this Agreement, “Licensed Back
Improvements” means any [*] by Licensee, any Affiliates [*], or any Sublicensees to any vector that is the subject of a claim within the Licensed Patents. 

2.5.2 Licensee agrees to provide prompt notice to Licensor upon the filing of any patent application covering any Licensed Back Improvement,
together with a reasonably detailed description of or access to such Licensed Back Improvement to permit the practice of any such invention or improvement by Licensor or its direct or indirect licensors or licensees. 

ARTICLE 3: CONSIDERATION 

3.1 Initial Fee. In consideration of the license granted to Licensee under Section 2.1, Licensee shall pay Licensor an initial fee
of $600,000 upon the Effective Date. One-half of the amount paid by Licensee to Licensor under this Section 3.1 may be paid by Licensee in the form of shares of Licensee’s common stock, which will be issued in accordance with
Section 3.8. 
 3.2 Annual Maintenance Fee. In consideration of the license granted to Licensee under Section 2.1, Licensee
shall pay Licensor on-going annual maintenance fees of [*] on each anniversary of the Effective Date. 
 3.3 Milestone Fees. In
consideration of the license granted to Licensee under Section 2.1, Licensee shall pay Licensor the following milestone payments on a per-Licensed Product basis: 
  

					
	 XLMTM Field Milestone
	  	Milestone Payment	 
	 1. First treatment of human subject in a clinical trial (i.e., first patient, first dose)
	  	 	[*]	  
	 2. First treatment in Phase 3 Clinical Trial (i.e., first patient, first dose)
	  	 	[*]	  
	 3. NDA submission in the United States
	  	 	[*]	  
	 4. NDA submission in the European Union
	  	 	[*]	  
	 5. NDA approval in the United States
	  	 	[*]	  
	 6. NDA approval in the European Union
	  	 	[*]	  
	 Total:
	  	$	8.85 million	  
		
	 Pompe Field Milestone
	  	Milestone Payment	 
	 1. First treatment of human subject in a clinical trial (i.e., first patient, first dose)
	  	 	[*]	  
	 2. First treatment in Phase 3 Clinical Trial (i.e., first patient, first dose)
	  	 	[*]	  
	 3. NDA submission in the United States
	  	 	[*]	  
	 4. NDA submission in the European Union
	  	 	[*]	  
	 5. NDA approval in the United States
	  	 	[*]	  
	 6. NDA approval in the European Union
	  	 	[*]	  
	 Total:
	  	$	8.85 million	  

  

					
		  	7	  	*Confidential Treatment Requested.

 3.3.1 At Licensee’s option, up to [*] of the amount paid by Licensee to Licensor under the
first milestones (i.e., first treatment of human study) for each of the XLMTM Field and the Pompe Field may be paid by Licensee in the form of shares of Licensee’s common stock, which will be issued in accordance with Section 3.8. 

3.3.2 For clarity, the milestone payments set forth in this Section 3.3 are payable [*] in the XLMTM Field and once in the Pompe Field
with respect to each Licensed Product that achieves the milestone event, regardless of whether the milestone is achieved by Licensee or any Sublicensee. To the extent that either of the two development milestones in this Section 3.3 with
respect to a particular field (i.e., first treatment of human subject in a clinical trial or first treatment in Phase 3 Clinical Trial) has not been paid at the time of achievement of either NDA submission milestone for that field, then, upon the
achievement of either of such NDA submission milestones, the preceding unpaid development milestone payments with respect to that field shall be made in addition to the payment corresponding to the NDA submission milestone that has been achieved.

 3.4 Royalties. In further consideration of the license granted to Licensee under Section 2.1, Licensee shall pay to Licensor
the following royalties based upon Net Sales of Licensed Products in the XLMTM Field or the Pompe Field, as applicable, subject to the reductions in royalty rates set forth in Section 3.4.1: 

 

					
	 Cumulative Annual Net Sales of all Licensed

Products in the XLMTM Field Worldwide
	  	Royalty Percentage for
XLMTM Field	 
	 Portion of Net Sales less than $300 million
	  	 	[	*] 
	 Portion of Net Sales between (and including) $300 million through (and including) $600 million
	  	 	[	*] 
	 Portion of Net Sales greater than $600 million
	  	 	[	*] 

  

					
	 Cumulative Annual Net Sales of all Licensed

Products in the Pompe Field Worldwide
	  	Royalty Percentage for
Pompe Field	 
	 Portion of Net Sales less than $300 million
	  	 	[	*] 
	 Portion of Net Sales between (and including) $300 million through (and including) $600 million
	  	 	[	*] 
	 Portion of Net Sales greater than $600 million
	  	 	[	*] 

 3.4.1 Third Party Royalties Stacking Provision. If Licensee must obtain a license from a Third Party to
avoid infringement of such Third Party’s rights in order to manufacture, use, or commercialize a given Licensed Product and if the royalties required to be paid to such Third Party for such license, together with those royalties payable to
Licensor, in the aggregate, exceed [*] of Net Sales for any Licensed Product, then the royalty owed to Licensor for that Licensed Product will be reduced by an amount calculated as follows: 

  

					
		  	8	  	*Confidential Treatment Requested.

 STACKING ROYAL TY CALCULATIONS 

R = (C * (A I (A+B))) 
 Where 

R = reduction of Licensor royalty, A = unreduced Licensor royalty, 

B = sum of all Third Party royalties, 

C = increment of projected total royalty above [*] 

Example Calculation: 
  

			
	assume:	  	i) all Third Party royalties = [*]
		  	ii) unreduced Licensor royalty = [*]
		  	iii) projected total royalty = [*]

  

	
	R = ([*] – [*]) * ([*] / ([*] + [*]))
	 R = ([*] * [*])

	 R = [*]

	 Licensor Stacked Royalty = [*] – [*] = [*]%

 Notwithstanding the foregoing, Licensee will pay to Licensor no less than [*]% of the royalties that Licensee
would otherwise pay to Licensor if there were no royalties due to Third Parties. 
 3.4.2 Royalty Payment Period. Licensee’s
obligation hereunder for payment of a royalty under this Section 3.4 on the Net Sales of Licensed Products in a given country will end on a country-by-country basis when all Valid Claims in that country claiming the Licensed Product have
expired, lapsed, been abandoned, or been invalidated. 
 3.5 Sublicense Fees. 

3.5.1 In further consideration of the license granted to Licensee under Section 2.1, Licensee will pay Licensor a percentage of any
sublicense fees (including upfront payments and milestone payments) received by Licensee for the Licensed Patents from any Sublicensee or from any person or entity granted any option to obtain a sublicense. The applicable percentage due to Licensor
for each sublicense (or option) shall be as follows: 
  

					
	 Event
	  	Sublicense Fee Rate	 
	 If sublicensed (or optioned) on or before the first anniversary of the Effective Date
	  	 	[	*] 
	 If sublicensed (or optioned) on or before the third anniversary of the Effective Date but after the first anniversary of the Effective
Date
	  	 	[	*] 
	 If sublicensed (or optioned) on or before the fourth anniversary of the Effective Date but after the third anniversary of the Effective
Date
	  	 	[	*] 
	 If sublicensed (or optioned) after the fourth anniversary of the Effective Date
	  	 	[	*] 

  

					
		  	9	  	*Confidential Treatment Requested.

 3.5.2 With respect to the obligations under this Section 3.5, Licensee shall not be required
to submit any amounts received from a Third Party for the following: 
 (a) Reimbursement for research, development, and/or manufacturing
activities performed by Licensee corresponding directly to the development of Licensed Products pursuant to a specific agreement; 
 (b)
Consideration received for the purchase of an equity interest in Licensee at fair market value or in the form of loans at commercially reasonable rates of interest; and 

(c) Any and all amounts paid to Licensee by a Sublicensee as royalties on sales of Licensed Product sold by the Sublicensee under a sublicense
agreement. 
 3.5.3 To the extent Licensee receives payment from a Third Party relating to one or more of the milestone events set forth in
the table in Section 3.3, then the amount of the payment made to Licensor under such Section 3.3 with respect to such milestone event shall be not be deemed sublicense fees under this Section 3.5; instead, the amounts due under this
Section 3.5 shall be calculated by applying the applicable sublicense fee rate set forth in Section 3.5.l above to the sublicense fees received by Licensee from such Third Party after deducting the amount of the payment under
Section 3.3. 
 3.6 Reports and Records. 

3.6.1 Licensee must deliver to Licensor within [*] after the end of each Calendar Quarter after the first commercial sale of a Licensed Product
a report setting forth the calculation of the royalties due to Licensor for such Calendar Quarter, including: 
 3.6.1.1 Number of Licensed
Products included within Net Sales, listed by country; 
 3.6.1.2 Gross consideration for Net Sales of Licensed Product, including all
amounts invoiced, billed, or received; 
 3.6.1.3 Qualifying costs to be excluded from the gross consideration, as described in
Section 1.16, listed by category of cost; 
 3.6.1.4 Net Sales of Licensed Products listed by country; 

3.6.1.5 A detailed accounting of any royalty reductions applied pursuant to Section 3.4.1; 

3.6.1.6 Royalties owed to Licensor, listed by category; and 

3.6.1.7 The computations for any applicable currency conversions. 

  

					
		  	10	  	*Confidential Treatment Requested.

 3.6.2 Licensee shall pay the royalties due under Section 3.4 within [*] following the last
day of the Calendar Quarter in which the royalties accrue. Licensee shall send the royalty payments along with the report described in Section 3.6.1. 

3.6.3 Within [*] after the occurrence of a milestone event described in Section 3.3, Licensee must deliver to Licensor a report describing
the milestone event that occurred, together with a payment of the applicable amount due to Licensor pursuant to Section 3.3. In addition, within [*] after the receipt of sublicense fees from any Sublicensee as described in Section 3.5,
Licensee must deliver to Licensor a report describing the fees received, together with a payment of the applicable amount due to Licensor pursuant to Section 3.5. 

3.6.4 All financial reports under this Section 3.6 will be certified by the chief financial officer of Licensee. 

3.6.5 Licensee shall maintain and require its Affiliates and all Sublicensees to maintain, complete and accurate books and records which enable
the royalties, fees, and payments payable under this Agreement to be verified. The records must be maintained for [*] after the submission of each report under Article 3. Upon reasonable prior written notice to Licensee, Licensee and its Affiliates
and all Sublicensees will provide Licensor and/or its direct or indirect licensors (and their respective accountants) with access to all of the relevant books, records, and related background information as reasonably required to confirm the
accuracy of the royalties, fees, and payments paid to Licensor under this Agreement. Access will be made available: (a) during normal business hours; (b) in a manner reasonably designed to facilitate the auditing party’s review or
audit without unreasonable disruption to Licensee’s business; and (c) no more than once each calendar year during the term of this Agreement and for a period of [*] thereafter. Licensee will promptly pay to Licensor the amount of any
underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Licensee has underpaid any payment by [*] or more, then Licensee will also promptly pay the costs and expenses of Licensor and or its
direct or indirect licensors and accountants in connection with the review or audit. 
 3.7 Currency, Interest. 

3.7.1 All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments to Licensor under this Agreement
must be made in United States dollars. 
 3.7.2 If Licensee receives payment in a currency other than United States dollars for which a
royalty or fee or other payment is owed under this Agreement, then (a) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal, as
of the last business day of the Calendar Quarter in which the payment was received by Licensee; and (b) the conversion computation will be documented by Licensee in the applicable report delivered to Licensor under Section 3.6. 

  

					
		  	11	  	*Confidential Treatment Requested.

 3.7.3 All amounts that are not paid by Licensee when due will accrue interest from the date due
until paid at a rate equal to 1.5% per month (or the maximum allowed by law, if less). 
 3.8 Issuance of Common Stock. If
Licensee elects to pay any amounts under Section 3.1 or 3.3.1 by the issuance of shares of Licensee’s common stock, then the provisions of this Section 3.8 will apply. 

3.8.1 Each share of Licensee’s common stock will be valued at [*] per share as of the Effective Date (the “Price Per
Share”) and shall be issued pursuant to the terms of the Common Stock Purchase Agreement in the form attached hereto as Exhibit C (the “Stock Purchase Agreement”). If Licensee at any time or from time to time after
the Effective Date effects a subdivision, split, or combination of Licensee’s outstanding common stock into a greater or lesser number of shares, then, in each such event, the Price Per Share in effect immediately prior to such subdivision,
split, or combination will be increased or decreased proportionately. Licensee will provide Licensor with written notice of any such subdivision, split, or combination and the resulting Price Per Share. 

3.8.2 The number of shares to be issued to Licensor will be determined by taking the amount of the payment owed under Section 3.1 or
3.3.1, as applicable, and dividing it by the Price Per Share, as calculated pursuant to Section 3.8.1. Licensee will deliver to Licensor, by no later than the date the payment (with respect to which Licensee will fulfill by the issuance of
shares of Licensee’s common stock) is due, (a) a copy of the Stock Purchase Agreement (executed by both Licensor and Licensee), (b) a stock certificate in the name of Licensee for the number of shares of common stock to be issued, and
(c) in connection with any issuance pursuant to Section 3.3.1, a certificate signed by an officer of Licensee attesting that Licensee’s representations and warranties contained in Sections 8.2.1 (with respect to Licensee’s
ability to issue the common stock), 8.2.4 (with respect to Licensee’s ability to issue the common stock), and 8.2.5 are true and correct as of the date of issuance of such stock with the same effect as though made on and as of such date. 

ARTICLE 4: DILIGENCE 

4.1 Licensee will use commercially reasonable efforts to develop, commercialize, market, promote, and sell Licensed Products in each of the
XLMTM Field and the Pompe Field. Commercially reasonable efforts means efforts equivalent to those utilized by [*] Without limiting the foregoing, Licensee will meet the following: 

(a) Acceptance by the FDA of an Investigational New Drug application for a Licensed Product in the XLMTM Field by no later than [*]; and 

(b) Acceptance by the FDA of an Investigational New Drug application for a Licensed Product in the Pompe Field by no later than [*]. 

Licensee will notify Licensor in writing as soon as Licensee believes in good faith that Licensee will not be able to achieve either milestone set forth in
Section 4.l (a) or (b) by the relevant deadline date, and, upon the payment to Licensor of [*] within [*] of the original deadline date, the deadline date for such milestone set forth in Section 4.l (a) or (b), as
applicable, will be extended for [*] from the original deadline date; provided that Licensee will only be entitled to [*] for the XLMTM Field and [*] for the Pompe Field, each of which extensions will require a payment of [*] as provided in this
Section 4.1. 

  

					
		  	12	  	*Confidential Treatment Requested.

 4.2 Within [*] after the Effective Date and within [*] of each December 1 thereafter,
Licensee shall provide Licensor with written progress reports, setting forth in such detail as Licensor may reasonably request, the progress of the development, evaluation, testing, and commercialization of each Licensed Product. Licensee will also
notify Licensor within [*] of the first commercial sale by Licensee, its Affiliates, or any Sublicensees of each Licensed Product. Such a report (“Development Progress Report”), setting forth the current stage of development of
Licensed Products, shall include: 
 4.2.1 Date of Development Progress Report and time covered by such report; 

4.2.2 Major activities and accomplishments completed by Licensee, its Affiliates, and any Sublicensees relating directly to the Licensed
Product since the last Development Progress Report; 
 4.2.3 Significant research and development projects relating directly to the Licensed
Product currently being performed by Licensee, its Affiliates, and any Sublicensees and projected dates of completion; 
 4.2.4 A development
plan covering the next two years at least, which will include future development activities to be undertaken by Licensee, its Affiliates, or any Sublicensees during the next reporting period relating directly to the Licensed Product, Licensee’s
strategy to bring the Licensed Product to commercialization, and projected timeline for completing the necessary tasks to accomplish the goals of the strategy; 

4.2.5 Projected total development remaining before product launch of each Licensed Product; and 

4.2.6 Summary of significant development efforts using the Licensed Patents being performed by Third Parties, including the nature of the
relationship between Licensee and such Third Parties. 
 4.3 The Parties agree that Development Progress Reports shall be deemed
Licensee’s Confidential Information; provided that Licensor may share a copy of such reports with its direct and indirect licensors. 

4.4 Simultaneously with the Development Progress Report, Licensee shall deliver a detailed description of any Licensed Back Improvements, if
not previously provided pursuant to Section 2.5.2. 
 ARTICLE 5: CONFIDENTIALITY 

5.1 Treatment of Confidential Information. Each Party, as a receiving party (a “Receiving Party”), agrees that it will
(a) treat Confidential Information of the other Party (the “Disclosing Party”) as strictly confidential; (b) not disclose such Confidential Information to 

  

					
		  	13	  	*Confidential Treatment Requested.

 
Third Parties without the prior written consent of the Disclosing Party, except as may be permitted in this Agreement; provided that any disclosure permitted hereunder be under confidentiality
agreements with provisions at least as stringent as those contained in this Agreement; and (c) not use such Confidential Information for purposes other than those authorized expressly in this Agreement. The Receiving Party agrees to ensure that
its employees who have access to Confidential Information are obligated in writing to abide by confidentiality obligations at least as stringent as those contained under this Agreement. 

5.2 Public Announcements. 

5.2.1 The Parties agree they will release a joint press release in the form attached hereto as Exhibit B. Except as provided in
Section 5.2.1, any other press releases by either Party with respect to the other Party or any other public disclosures concerning the existence of or terms of this Agreement shall be subject to review and approval by the other Party. Once the
joint press release or any other written statement is approved for disclosure by both Parties, either Party may make subsequent public disclosure of the contents of such statement without the further approval of the other Party. 

5.2.2 Notwithstanding Section 5.2.1, Licensor has the right to publish (through press releases, scientific journals, or otherwise) and
refer to any clinical, regulatory, or research results related to Licensee’s Licensed Product or AAV8 or AAV9 program that have been publicly disclosed by Licensee, including referring to Licensee by name as a licensee of Licensor, which
publication or referral by Licensor shall not require the prior consent of Licensee. 
 5.3 Authorized Disclosure. Notwithstanding the
provisions of Section 5.1 or 5.2, either Party may disclose Confidential Information or make such a disclosure of the existence of and/or terms of this Agreement to any [*]; provided that, in each case, such recipient of Confidential
Information is obligated to keep such information confidential on terms no less stringent than those set forth in this Agreement. Furthermore, Licensee agrees that Licensor may share a copy of this Agreement, reports and notices provided by Licensee
to Licensor pursuant to the terms of this Agreement, and copies of sublicense agreements provided to Licensor hereunder with any of Licensor’s direct and indirect licensors of the Licensed Patents. In the event that the Receiving Party receives
service of legal process that purports to compel disclosure of the Disclosing Party’s Confidential Information or becomes obligated by law to disclose the Confidential Information of the Disclosing Party or the existence of or terms of this
Agreement to any governmental authority, the Receiving Party shall promptly notify the Disclosing Party, so that the Disclosing Party may seek an appropriate protective order or other remedy with respect to narrowing the scope of such requirement
and/or waive compliance by the Receiving Party with the provisions of this Agreement. The Receiving Party will provide the Disclosing Party with reasonable assistance in obtaining such protective order or other remedy. If, in the absence of such
protective order or other remedy, the Receiving Party is nonetheless required by law to disclose the existence of or terms of this Agreement or other Confidential Information of the Disclosing Party, the Receiving Party may disclose such
Confidential Information without liability hereunder; provided that the Receiving Party shall furnish only such portion of the Confidential Information that is legally required to be disclosed and only to the extent required by law. 

  

					
		  	14	  	*Confidential Treatment Requested.

 5.4 Term of Confidentiality. The obligations of this Article 5 shall continue for a period
of [*] following the expiration or termination of this Agreement. 
 ARTICLE 6: TERM AND TERMINATION 

6.1 Term of Agreement. This Agreement, unless sooner terminated as provided in this Agreement, expires upon the expiration, lapse,
abandonment, or invalidation of the last Valid Claim to expire, lapse, or become abandoned or unenforceable in all countries of the world. 

6.2 Licensee’s Right to Terminate. Licensee may, upon 90 days’ prior written notice to Licensor, terminate this Agreement for
any reason, with or without cause. In exercising such termination right, Licensee may terminate the Agreement in its entirety or, if desired, Licensee may specify in the written notice that this Agreement is terminating only with respect to either
the Pompe Field or the XLMTM Field. 
 6.3 Termination for Breach. 

6.3.1 Licensor may terminate this Agreement, if Licensee is late in paying to Licensor royalties, fees, or any other monies due under this
Agreement, and Licensee does not pay Licensor in full within 15 days upon written demand from Licensor, which termination shall be effective immediately upon the expiration of such 15-day cure period. 

6.3.2 Either Party may terminate this Agreement, if the other Party materially breaches this Agreement and does not cure such material breach
within 30 days after written notice of the breach, which termination shall be effective immediately upon the expiration of such 30-day cure period; provided that, if termination is by Licensor as a result of Licensee’s materially breaching
Article 4, and if such breach only relates to either the Pompe Field or XLMTM Field, but not both, then Licensor’s termination right shall only be with respect to the Pompe Field or XLMTM Field, as applicable, with respect to which the breach
related and not both. Notwithstanding the above, if Licensee disputes in good faith that such material breach exists, and gives Licensor written notice of such dispute within 30 days following Licensee’s receipt of Licensor’s notice of
default, then, Licensor may not terminate this Agreement until the dispute is resolved in accordance with Section 10.6; provided that Licensor shall be entitled to terminate this Agreement at the end of the original 30-day cure period, without
waiting for resolution of the dispute in accordance with Section 10.6, if the breach by Licensee of this Agreement would cause Licensor to be in breach of the GSK Agreement or the Penn Agreement. 

6.4 Termination for Insolvency. 

6.4.1 Licensor may terminate this Agreement, effective immediately upon written notice to Licensee, if Licensee or any of its Affiliates
experiences any Trigger Event. 
 6.4.2 Licensee shall include in each sublicense agreement entered into with a Sublicensee a right of
Licensee to terminate such sublicense agreement if such Sublicensee experiences any Trigger Event; and Licensee shall terminate the sublicense agreement, effective immediately upon written notice to the Sublicensee, if the Sublicensee experiences
any Trigger Event. In addition, if the Sublicensee’s experiencing of a Trigger Event gives Licensor’s 

  

					
		  	15	  	*Confidential Treatment Requested.

 
licensor a right of termination under the Penn Agreement and such licensor provides written notice of such termination to Licensor, then, upon receipt of such notice, Licensor may terminate this
Agreement, effective immediately upon written notice to Licensee, if any Sublicensee experiences any Trigger Event. 
 6.4.3 For purposes of
this Section 6.4, “Trigger Event” means any of the following: (a) if Licensee, any Affiliate, or any Sublicensee, as applicable, (i) becomes insolvent, becomes bankrupt, or generally fails to pay its debts as such
debts become due, (ii) is adjudicated insolvent or bankrupt, (iii) admits in writing its inability to pay its debts, (iv) suffers the appointment of a custodian, receiver, or trustee for it or its property and, if appointed without
its consent, such appointment is not discharged within 30 days, (v) makes an assignment for the benefit of creditors, or (vi) suffers proceedings being instituted against it under any law related to bankruptcy, insolvency, liquidation, or
the reorganization, readjustment, or release of debtors and, if contested by it, not dismissed or stayed within ten days; (b) the institution or commencement by Licensee, any Affiliate, or any Sublicensee, as applicable, of any proceeding under
any law related to bankruptcy, insolvency, liquidation, or the reorganization, readjustment, or release of debtors; (c) the entering of any order for relief relating to any of the proceedings described in Section 6.4.3(a) or
(b) above; (d) the calling by Licensee, any Affiliate, or any Sublicensee, as applicable, of a meeting of its creditors with a view to arranging a composition or adjustment of its debts; or (e) the act or failure to act by Licensee,
any Affiliate, or any Sublicensee, as applicable, indicating its consent to, approval of, or acquiescence in any of the proceedings described in Section 6.4.3(b) through (d) above. 

6.5 Patent Challenge. 

6.5.1 Licensor may terminate this Agreement, effective immediately upon written notice to Licensee, upon the commencement by Licensee or any of
its Affiliates of a Patent Challenge. 
 6.5.2 Licensee shall include in each sublicense agreement entered into with a Sublicensee a right of
Licensee to terminate such sublicense agreement if such Sublicensee commences a Patent Challenge; and Licensee shall terminate the sublicense agreement, effective immediately upon written notice to the Sublicensee, if the Sublicensee commences a
Patent Challenge. In addition, if the Sublicensee’s commencement of a Patent Challenge gives Licensor’s licensor a right of termination under the Penn Agreement and such licensor provides written notice of such termination to Licensor,
then, upon receipt of such notice, Licensor may terminate this Agreement, effective immediately upon written notice to Licensee, if any Sublicensee commences a Patent Challenge. 

6.5.3 For purposes of this Section 6.5, “Patent Challenge” means any action against Licensor, the University of
Pennsylvania, or any direct or indirect licensor of Licensor (including an action for declaratory judgment) to declare, or render invalid or unenforceable the Licensed Patents, or any claim thereof. 

  

					
		  	16	  	

 6.6 Effects of Termination. The effect of termination by Licensee pursuant to
Section 6.2, by either Party, as applicable, under Section 6.3, or by Licensor pursuant to Section 6.4 or 6.5 shall be as follows: 

6.6.1 The licenses granted by Licensor hereunder shall terminate, and Licensee and its Affiliates shall cease to make, have made, use, import,
sell, and offer for sale all Licensed Products and shall cease to otherwise practice the Licensed Patents; provided that Licensee shall have the right to continue to sell its existing inventories of Licensed Products for a period not to exceed [*]
after the effective date of such termination; 
 6.6.2 All sublicenses granted to Third Parties to the extent of the rights licensed to
Licensee hereunder and sublicensed to the Sublicensee shall be assigned to Licensee; provided that (i) prior to such assignment, Licensee shall advise Licensor whether such Sublicensee is then in full compliance with all terms and conditions of
its sublicense and continues to perform thereunder, and, if such Sublicensee is not in full compliance or is not continuing to perform, Licensor may elect not to have such sublicense assigned; and (ii) following such assignment, Licensor shall
not be liable to such Sublicensee with respect to any obligations of Licensee to the Sublicensee that are not consistent with, or not required by, Licensor’s obligations to Licensee under this Agreement; 

6.6.3 If termination is by Licensee pursuant to Section 6.2 or by Licensor pursuant to Section 6.3, 6.4, or 6.5, Licensee shall
grant, and hereby grants to Licensor a non-exclusive, perpetual, irrevocable, worldwide, royalty-free, transferable, sublicensable license under any patentable modifications or improvements (and any intellectual property rights with respect thereto)
developed by Licensee, any Affiliates (excluding any such modifications or improvements developed by a Third Party that acquired Licensee or its Affiliates, whether by merger, acquisition or assets sale, prior to the date of such acquisition), or
any Sublicensees to any vector that is the subject of a claim within any of the Licensed Patents, for use by Licensor for the research, development, and commercialization of products in any therapeutic indication; 

6.6.4 Licensee shall pay all monies then-owed to Licensor under this Agreement; and 

6.6.5 Each Receiving Party shall, at the other Party’s request, return all Confidential Information of the Disclosing Party.
Notwithstanding the foregoing, one copy may be kept by either Party for a record of that Party’s obligations. 
 If termination is only with respect to
either the Pompe Field or the XLMTM Field, but not both, then the provisions of this Section 6.6 shall only apply with respect to the terminated Field, and this Agreement shall continue with respect to the non-terminated Field. 

6.7 Survival. Licensee’s obligation to pay all monies due and owed to Licensor under this Agreement which have matured as of the
effective date of termination or expiration shall survive the termination or expiration of this Agreement. In addition, the provisions of Section 2.2, (Retained Rights), 2.3 (Government Rights), 2.5 (Improvements), Article 3 (Consideration)
(with respect to any final reports or to the extent any amounts are due but unpaid), Section 3.6 (Reports and Records), Article 5 (Confidentiality), Article 6 (Term and Termination), Section 8.3 (Disclaimer of Warranties, Damages),
Section 8.4 (Indemnification), Section 8.5 (Insurance), Article 9 (Use of Name), and Article 10 (Additional Provisions) shall survive such termination or expiration of this Agreement in accordance with their respective terms. 

  

					
		  	17	  	*Confidential Treatment Requested.

 ARTICLE 7: PATENT MAINTENANCE; PATENT INFRINGEMENT 

7.1 Prosecution of Licensed Patents. As between Licensor and Licensee, the Parties agree as follows: 

7.1.1 Licensor shall have the sole right, but not the obligation, to Prosecute patent applications and issued patents within Licensed Patents,
in Licensor’s sole discretion. Subject to Section 7.1.3, Licensor shall provide Licensee with a reasonable opportunity to review and provide comments in connection with the Prosecution of the Licensed Patents; and Licensor shall keep
Licensee reasonably informed as to all material developments with respect to such Licensed Patents and shall supply to Licensee copies of material communications received and filed in connection with the Prosecution of such Licensed Patents. 

7.1.2 Nothing in this Agreement obligates Licensor to continue to Prosecute any patent applications or issued patents, and Licensee
acknowledges that Licensor shall have no obligation to undertake any inter-party proceedings, such as oppositions or interferences, or to undertake any re-examination or re-issue proceedings, in either case, with respect to the Licensed Patents.

 7.1.3 Licensee acknowledges that the University of Pennsylvania controls Prosecution of the Licensed Patents, with Licensor having certain
rights to review. Licensee acknowledges and agrees the rights and obligations under this Section 7.1 are subject to the rights of Licensor’s direct and indirect licensors with respect to the Licensed Patents and Licensor’s obligations
under this Agreement only apply to the extent of Licensor’s rights with respect to participation in Prosecuting the Licensed Patents under its agreements with its direct and indirect licensors. 

7.2 Infringement Actions Against Third Parties. 

7.2.1 Licensee is responsible for notifying Licensor promptly of any infringement of Licensed Patents (other than Retained Rights) that may
come to Licensee’s attention. Licensee and Licensor shall consult one another in a timely manner concerning any appropriate response to the infringement. 

7.2.2 As between Licensor and Licensee, Licensor shall have the first right, but not the obligation, to prosecute any such infringement at its
own expense. In any action to enforce any of the Licensed Patents, Licensee, at the request and expense of Licensor, shall cooperate to the fullest extent reasonably possible, including in the event that, if Licensor is unable to initiate or
prosecute such action solely in its own name, Licensee shall join such action voluntarily and shall execute all documents necessary to initiate litigation to prosecute and maintain such action. 

7.2.3 If Licensor elects not to pursue any infringement of a Licensed Patent, then, to the extent that a Licensed Product is covered by any
such License Patent and such Licensed Patent is being infringed by another product in the Field (such infringement, the “Competitive Infringement”), Licensee shall have the second right, but not the obligation, to prosecute such
Competitive Infringement with respect to such other product in the Field, at Licensee’s own expense. In any such action to enforce any of the Licensed Patents, Licensor, at 

  
 18 

 
the request and expense of Licensee, shall cooperate to the fullest extent reasonably possible, including in the event that, if Licensee is unable to initiate or prosecute such action solely in
its own name, Licensor shall join such action voluntarily and shall execute all documents necessary to initiate litigation to prosecute and maintain such action. In prosecuting any such Competitive Infringement, Licensee (a) shall not take any
actions that would be detrimental to the Licensed Patents and Licensor’s rights with respect thereto outside the Field and (b) shall not settle any such Competitive Infringement without the prior consent of Licensor. 

7.2.4 Any recovery of damages by Licensor for any infringement other than a Competitive Infringement shall be [*]. Any recovery of damages by
the Party undertaking enforcement or defense of a suit for Competitive Infringement shall be applied, as between Licensor and Licensee but subject to the obligations to Licensor’s direct and indirect licensors, first to reimburse each such
Party for costs and expenses (including reasonable attorneys’ fees and costs) incurred by such Party in connection with such suit, and the balance remaining, if any, from any such recovery shall be [*]. 

7.2.5 Licensee acknowledges and agrees that (a) the rights and obligations under this Section 7.2 are subject to the rights of
Licensor’s direct and indirect licensors of the Licensed Patents (including any consent or approval rights or rights to control or participate in any enforcement actions); and (b) Licensor’s obligations under this Agreement only apply
to the extent that Licensor has any rights with respect to enforcing the Licensed Patents under its agreements with its direct and indirect licensors. Furthermore, Licensee acknowledges the following: 

7.2.5.1 All monies recovered upon the final judgment or settlement of any action with respect to Competitive Infringement will also need to be
allocated to Licensor’s direct and indirect licensors (a) to reimburse the costs and expenses (including reasonable attorneys’ fees and costs) of such licensors, (b) to take into account the royalties payable to such licensors;
and (c) to take into account the relative extent of such licensors’ financial participation in such action, if applicable. 

7.2.5.2 Licensor’s direct and indirect licensors retain the continuing right to intervene at their own expense and join Licensor or
Licensee in any claim or suit for infringement of the Licensed Patents. 
 7.2.5.3 In any infringement prosecuted by Licensors’ direct
and indirect licensors, all financial recoveries will be [*]. 
 7.2.5.4 In any infringement prosecuted by Licensor’s direct and
indirect licensors, Licensee agrees, at the request and expense of such licensors, to cooperate to the fullest extent reasonably possible, to the same extent as though Licensor were prosecuting such suit (as provided in this Section 7.2,
including Section 7.2.2). 
 7.2.5.5 The written consent of Licensor’s direct and indirect licensors will be required (a) for
any decision that would have a materially adverse affect on the validity, scope of patent claims, or enforceability of the Patent Rights and (b) for any settlement or compromise of any infringement suit that would impose any obligations or
restrictions on any of its direct or indirect licensors, or grants any rights to the Licensed Patents other than rights that Licensee has the right to grant under this Agreement. 

  

					
		  	19	  	*Confidential Treatment Requested.

 7.3 Defense of Infringement Claims. In the event Licensee or Licensor becomes aware that
Licensee’s or any of its Affiliates’ or any Sublicensees’ practice of the Licensed Patents is the subject of a claim for patent infringement by a Third Party, that Party shall promptly notify the other, and the Parties shall consider
the claim and the most appropriate action to take. Licensee shall cause each of its Affiliates and each Sublicensee to notify Licensee promptly in the event such entity becomes aware that its practice of the Licensed Patents is the subject of a
claim of patent infringements by another. To the extent Licensor takes any action, Licensor (or its direct or indirect licensors) shall have the right to require Licensee’s reasonable cooperation in any such suit, upon written notice to
Licensee; and Licensee shall have the obligation to participate upon Licensor’s request, in which event, Licensor shall bear the cost of Licensee’s participation. Without Licensor’s prior written permission, Licensee must not settle
or compromise any such suit in a manner that imposes any material obligations or restrictions on Licensor or any of its direct or indirect licensors or grants any rights to the Licensed Patents other than rights that Licensee has the right to grant
under this Agreement. 
 ARTICLE 8: WARRANTIES; INDEMNIFICATION 

8.1 Warranty by Licensor. Licensor represents and warrants to Licensee as of the Effective Date: 

8.1.1 Licensor has the right, power, and authority to enter into this Agreement and to grant to Licensee the rights specified in this
Agreement; 
 8.1.2 This Agreement when executed shall become the legal, valid and binding obligation of it, enforceable against it, in
accordance with its terms; 
 8.1.3 There are no actions, suits, proceedings, or arbitrations pending or, to the Licensor’s knowledge,
threatened against Licensor relating to the Licensed Patents that would impact activities under this Agreement; 
 8.1.4 To Licensor’s
knowledge, (a) the Licensed Patents are solely owned by the University of Pennsylvania, and {b) no Third Party (other than Licensor’s direct and indirect licensors) has any right, interest, or claim in or to such Licensed Patents in the
Field that are inconsistent with those granted to Licensee herein; 
 8.1.5 To Licensor’s knowledge, Licensor does not Control as of the
Effective Date any patent or patent application (other than the Licensed Patents (as defined in Section l.13(a)) that would necessarily be infringed by the use or sale of AAV8 or AAV9 in the Field. If it is determined, in accordance with the
procedure of this Section 8.1.5, that Licensor Controls as of the Effective Date a patent or patent application (other than the Licensed Patents) that would necessarily be infringed by the use or sale of AAV8 or AAV9 in the Field, then
Licensee’s sole remedy shall be the inclusion of the applicable patent or patent application as a “Licensed Patent” hereunder but solely to the extent of the claim(s) that would necessarily be infringed by the use or sale of AAV8 or
AAV9. At any time during the term of this Agreement, Licensee may notify Licensor in writing of any such patent or patent application that Licensee believes 

  
 20 

 
should be included as a “Licensed Patent” pursuant to this Section 8.1.5. Such written notice shall identify the relevant patent or patent application and relevant claim(s) and
shall explain briefly why Licensee, in good faith, believes it should be included as a “Licensed Patent.” Licensor has [*] following Licensor’s receipt of Licensee’s written notice to dispute the inclusion of such patent or
patent application or the scope of the remedy; in which event, such dispute will be resolved in accordance with Section 10.6. Upon the Parties’ agreement (or a resolution, in favor of Licensee, of the dispute pursuant to
Section 10.6), the applicable claim(s) of the applicable patent or patent application will be deemed a “Licensed Patent” hereunder. For the avoidance of doubt, Licensor makes no representation or warranty under this Section 8.1.5
as to any claim of a patent or patent application covering the manufacture of AAV8 or AAV9, and Licensee acknowledges that manufacturing claims of any patents or patent applications will not be added as “Licensed Patents” pursuant to the
procedure set forth in this Section 8.1.5. For the purpose of this Section 8.1.5, “Control” means the possession by Licensor (whether by ownership or license, other than pursuant to this Agreement) of the ability to grant to
Licensee access, a license, or a sublicense (as applicable) to the applicable patent or patent application on the terms and conditions set forth herein without violating the terms of any agreement or other arrangement with any Third Party; 

8.1.6 To Licensor’s knowledge, no Third Party is infringing any of the Licensed Patents in the Field; and 

8.1.7 Licensor has not received any written notice from any Third Party patentee alleging infringement of, and to Licensor’s knowledge
Licensor has not been sued for patent infringement of, Third Party technology by the practice of the Licensed Patents in the Field. 
 8.2
Warranty by Licensee. Licensee represents and warrants to Licensor as of the Effective Date that: 
 8.2.1 Licensee has the right,
power, and authority to enter into this Agreement, to grant the rights granted by it hereunder, and to issue Licensee’s common stock to Licensor in accordance with this Agreement; 

8.2.2 This Agreement when executed shall become the legal, valid and binding obligation of it, enforceable against it, in accordance with its
terms; 
 8.2.3 Licensee has the ability and the resources, including financial resources, necessary to carry out its obligations under this
Agreement; 
 8.2.4 There are no actions, suits, proceedings, or arbitrations pending or, to the Licensee’s knowledge, threatened
against Licensee that would impact activities under this Agreement; and 
 8.2.5 Licensee’s common stock, when issued and delivered in
accordance with the terms of Article 3, (a) will be duly and validly authorized and issued, fully paid and non-assessable, and free from all taxes, liens, and charges created by Licensee in respect of the
issuance thereof, (b) will be issued in compliance with all applicable federal and state securities laws, and (c) will be free of transfer restrictions (other than the transfer restrictions imposed by any federal or state securities laws
and liens or encumbrances created by or imposed by Licensor). 

  

					
		  	21	  	*Confidential Treatment Requested.

 8.3 Disclaimer of Warranties, Damages. EXCEPT AS SET FORTH IN SECTION 8.1, THE LICENSED
PATENTS, LICENSED PRODUCTS, AND ALL RIGHTS LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS, AND LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO. BY WAY OF EXAMPLE BUT NOT OF
LIMITATION, LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, AND HEREBY DISCLAIMS ALL EXPRESS AND IMPLIED REPRESENTATIONS AND WARRANTIES, (i) OF COMMERCIAL UTILITY, ACCURACY, COMPLETENESS, PERFORMANCE, MERCHANTABILITY, FITNESS FOR A PARTICULAR
PURPOSE, VALIDITY OR ENFORCEABILITY OF THE LICENSED PATENTS, AND PROFITABILITY; OR (ii) THAT THE USE OF THE LICENSED PATENTS OR LICENSED PRODUCTS WILL NOT INFRINGE ANY PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF THIRD PARTIES.
EXCEPT AS SET FORTH HEREIN, NONE OF LICENSOR OR ANY OF LICENSOR’S DIRECT OR INDIRECT LICENSORS SHALL BE LIABLE TO LICENSEE, LICENSEE’S SUCCESSORS OR ASSIGNS, ANY SUBLICENSEES, OR ANY THIRD PARTY WITH RESPECT TO: (a) ANY CLAIM ARISING
FROM USE OF THE LICENSED PATENTS, LICENSED PRODUCTS, AND ANY OR ALL RIGHTS LICENSED UNDER THIS AGREEMENT OR FROM THE DEVELOPMENT, TESTING, MANUFACTURE, USE, OR SALE OF LICENSED PRODUCTS; OR (b) ANY CLAIM FOR LOSS OF PROFITS, LOSS OR
INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ANY ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT OR THE EXERCISE OF RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF
SUCH DAMAGES. NOTHING IN THIS SECTION 8.3 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER SECTION 8.4 OR TO LIMIT A PARTY’S LIABILITY FOR BREACHES OF ITS OBLIGATION REGARDING CONFIDENTIALITY
UNDER ARTICLE 5. 
 8.4 Indemnification. 

8.4.1 By Licensee. Licensee shall defend, indemnify, and hold harmless Licensor, its direct and indirect licensors of the Licensed
Patents, and their respective shareholders, members, officers, trustees, faculty, students, contractors, agents, and employees (individually, a “Licensor Indemnified Party” and, collectively, the “Licensor Indemnified
Parties”) from and against any and all Third Party liability, loss, damage, action, claim, fee, cost, or expense (including attorneys’ fees) (individually, a “Third Party Liability” and, collectively, the
“Third Party Liabilities”) suffered or incurred by the Licensor Indemnified Parties from claims of such Third Parties that results from or arises out of: [*]; provided, however, that Licensee shall not be liable for claims based on
any breach by Licensor of the representations, warranties, or obligations of this Agreement or the gross negligence or intentional misconduct of any of the Licensor Indemnified Parties. Without limiting the foregoing, Licensee must defend,
indemnify, and hold harmless the Licensor Indemnified Parties from and against any Third Party Liabilities resulting from: 

  

					
		  	22	  	*Confidential Treatment Requested.

 8.4.1.1 any [*] or other claim of any kind related to the [*] by a Third Party of a Licensed
Product that [*] by Licensee, its Affiliates, any Sublicensees, their respective assignees, or vendors; 
 8.4.1.2 any claim by a Third
Party that the [*]; and 
 8.4.1.3 [*] conducted by or on behalf of Licensee, its Affiliates, any Sublicensees, their respective assignees,
or vendors relating to the Licensed Patents or Licensed Products, including any claim by or [*]. 
 8.4.2 By Licensor. Licensor shall
defend, indemnify, and hold harmless Licensee, its shareholders, members, officers, contractors, agents, and employees (individually, a “Licensee Indemnified Party” and, collectively, the “Licensee Indemnified
Parties”) from and against any and all Third Party Liabilities suffered or incurred by the Licensee Indemnified Parties from claims of such Third Parties that results from or arises out of: [*]; provided, however, that Licensor shall not be
liable for claims based on any breach by Licensee of the representations, warranties, or obligations of this Agreement or the gross negligence or intentional misconduct of any of the Licensee Indemnified Parties. 

8.4.3 Indemnification Procedure. Each Party, as an indemnifying party (a “Indemnifying Party”), shall not be permitted
to settle or compromise any claim or action giving rise to Third Party Liabilities in a manner that imposes any restrictions or obligations on any indemnified party (a “Indemnified Party”) without the other Party’s prior
written consent or, if Licensee is the Indemnifying Party, that grants any rights to the Licensed Patents or Licensed Products other than those Licensee has the right to grant under this Agreement without Licensor’s prior written consent. The
Indemnifying Party shall be permitted to control any litigation or potential litigation involving the defense of any claim subject to indemnification pursuant to this Section 8.4, including the selection of counsel, with the reasonable approval
of the Indemnified Party. If an Indemnifying Party fails or declines to assume the defense of any such claim or action within [*] after notice thereof, the Indemnified Party may assume the defense of such claim or action at the cost and risk of the
Indemnifying Party, and any Third Party Liabilities related thereto shall be conclusively deemed a Third Party Liability of the Indemnifying Party. The indemnification rights of a Indemnified Party contained in this Agreement are in addition to all
other rights which such Indemnified Party may have at law or in equity or otherwise. The Indemnifying Party will pay directly all Third Party Liabilities incurred for defense or negotiation of any claim hereunder or will reimburse the Indemnified
Party for all documented Third Party Liabilities incident to the defense or negotiation of any such claim within [*] after the Indemnifying Party’s receipt of invoices for such fees, expenses, and charges. 

8.5 Insurance. Licensee will procure and maintain insurance policies for the following coverages with respect to product liability,
personal injury, bodily injury, and property damage arising out of Licensee’s (and its Affiliates’ and any Sublicensees’) performance under this Agreement: (a) during the term of this Agreement, comprehensive general liability,
including broad form and contractual liability, in a minimum amount of [*] combined single limit per occurrence (or claim) and in the aggregate annually; (b) prior to the commencement of clinical trials involving Licensed Products and
thereafter for a period of not less than [*] (or such longer period as Licensee is required by applicable law to continue to monitor the participants in 

  

					
		  	23	  	*Confidential Treatment Requested.

 
the clinical trial), clinical trials coverage in amounts that are reasonable and customary in the U.S. pharmaceutical industry, subject always to a minimum limit of [*] combined single limit per
occurrence (or claim) and in the aggregate annually; and (c) from prior to the first commercial sale of a Licensed Product until [*] after the last sale of a Licensed Product, product liability coverage, in amounts that are reasonable and
customary in the U.S. pharmaceutical industry, subject always to a minimum limit of [*] combined single limit per occurrence (or claim) and in the aggregate annually. Licensor may review periodically the adequacy of the minimum amounts of insurance
for each coverage required by this Section 8.5, and Licensor reserves the right to require Licensee to adjust the limits accordingly. The required minimum amounts of insurance do not constitute a limitation on Licensee’s liability or
indemnification obligations to the Licensor Indemnified Parties under this Agreement. The policies of insurance required by this Section 8.5 will be issued by an insurance carrier with an A.M. best rating of [*] or better and will name Licensor
as an additional insured with respect to Licensee’s performance (and its Affiliates’ and any Sublicensees’) under this Agreement. Licensee will provide Licensor with insurance certificates evidencing the required coverage within [*]
after the Effective Date and the commencement of each policy period and any renewal periods. Upon Licensor’s written request, each certificate will provide that the insurance carrier will notify Licensor in writing at least [*] prior to the
cancellation or material change in coverage. Licensee will cause all Sublicensees to comply with the terms of this Section 8.5 to the same extent as Licensee. 

ARTICLE 9: USE OF NAME 

Licensee, its Affiliates, any Sublicensees, and all of its and their employees and agents must not use Licensor’s, the University of
Pennsylvania’s, or SmithKline Beecham Corporation’s name, seal, logo, trademark, or service mark (or any adaptation thereof) or the name, seal, logo, trademark, or service mark (or any adaptation thereof) of any of such entities’
representative, school, organization, employee, or student in any way without the prior written consent of Licensor or such entity, as applicable; provided, however that Licensee may acknowledge the existence and general nature of this Agreement.

 ARTICLE 10: ADDITIONAL PROVISIONS 

10.1 Relationship. Nothing in this Agreement shall be deemed to establish a relationship of principal and agent between Licensee and
Licensor, nor any of their agents or employees for any purpose whatsoever, nor shall this Agreement be construed as creating any other form of legal association or arrangement which would impose liability upon one Party for the act or failure to act
of the other Party. 
 10.2 Assignment. The rights and obligations of Licensee and Licensor hereunder shall inure to the benefit of,
and shall be binding upon, their respective permitted successors and assigns. Licensee may not assign this Agreement or any of its rights or obligations under this Agreement without the prior written consent of Licensor; provided, however, that
Licensee may assign this Agreement, without Licensor’s prior written consent, pursuant to a merger or sale of all or substantially all of the assets to which the Agreement relates; provided that, as part of any permitted assignment,
(a) Licensee provides Licensor with notice of such assignment at least 5 business days prior to the effectiveness of such assignment, and (b) Licensee requires any such assignee to agree in writing to be legally bound by this Agreement to
the same extent as Licensee 
  

  

					
		  	24	  	*Confidential Treatment Requested.

 
and provides Licensor with a copy of such assignee undertaking. Licensor may assign this Agreement and its rights and obligations without the consent of Licensee. No assignment shall relieve the
assigning Party of responsibility for the performance of any accrued obligations which it has prior to such assignment. Any attempted assignment by Licensee in violation of this Section 10.2 shall be null and void and of no legal effect. 

10.3 Waiver. A waiver by either Party of a breach of any provision of this Agreement will not constitute a waiver of any subsequent
breach of that provision or a waiver of any breach of any other provision of this Agreement. 
 10.4 Notices. Notices, payments,
statements, reports, and other communications under this Agreement shall be in writing and shall be deemed to have been received as of the date received if sent by public courier (e.g., Federal Express), by Express Mail, receipt requested, or
by facsimile (with a copy of such facsimile also sent by one of the other methods of delivery) and addressed as follows: 
  

			
	If for Licensor:	  	with a copy to:
		
	ReGenX Biosciences, LLC	  	ReGenX Biosciences, LLC
	750 17th Street, NW	  	750 17th Street, NW
	Suite 1100	  	Suite 1100
	Washington, DC 20006	  	Washington, DC 20006
	Attn: Chief Executive Officer	  	Attn: General Counsel
	Telephone: 202-785-7438	  	Telephone: 202-785-7438
	Facsimile: 202-785-7439	  	Facsimile: 202-785-7439
		
	If for Licensee:	  	with a copy to:
		
	Audentes Therapeutics, Inc.	  	Fenwick and West, LLP.
	[*]	  	1191 Second Avenue, 10th Floor
	San Francisco, California, [*]	  	Seattle, WA 98101
	Attn: Matthew Patterson, President & CEO	  	Attn: Effie Toshav
	Telephone: 646-712-1001	  	Telephone: 206.389.4510
	Email: mpatterson@audentestx.com	  	Facsimile: 206-389-4511

 Either Party may change its official address upon written notice to the other Party. 

10.5 Applicable Law. This Agreement shall be construed and governed in accordance with the laws of the State of Delaware, without giving
effect to conflict of law provisions that may require the application of the laws of another jurisdiction. Subject to Section 10.6, the Parties hereby submit to the exclusive jurisdiction of and venue in the courts located in the State of
Delaware with respect to any and all disputes concerning the subject of this Agreement. 
 10.6 Dispute Resolution. In the event of
any controversy or claim arising out of or relating to this Agreement, the Parties shall first attempt to resolve such controversy or claim through good faith negotiations for a period of not less than [*] following notification of such controversy
or claim to the other Party. If such controversy or claim cannot be resolved by 

  

					
		  	25	  	*Confidential Treatment Requested.

 
means of such negotiations during such period, then such controversy or claim shall be resolved by binding arbitration administered by the American Arbitration Association (“AAA”) in
accordance with the Commercial Arbitration Rules of the AAA in effect on the date of commencement of the arbitration, subject to the provisions of this Section 10.6. The arbitration shall be conducted as follows: 

10.6.1 The arbitration shall be conducted by three arbitrators, each of whom by training, education, or experience has knowledge of the
research, development, and commercialization of biological therapeutic products in the United States. The arbitration shall be conducted in English and held in New York, New York. 

10.6.2 In its demand for arbitration, the Party initiating the arbitration shall provide a statement setting forth the nature of the dispute,
the names and addresses of all other parties, an estimate of the amount involved (if any), the remedy sought, otherwise specifying the issue to be resolved, and appointing one neutral arbitrator. In an answering statement to be filed by the
responding Party within [*] after confirmation of the notice of filing of the demand is sent by the AAA, the responding Party shall appoint one neutral arbitrator. Within [*] from the date on which the responding Party appoints its neutral
arbitrator, the first two arbitrators shall appoint a chairperson. 
 10.6.3 If a Party fails to make the appointment of an arbitrator as
provided in Section 10.6.2, the AAA shall make the appointment. If the appointed arbitrators fail to appoint a chairperson within the time specified in Section 10.6.2 and there is no agreed extension of time, the AAA shall appoint the
chairperson. 
 10.6.4 The arbitrators will render their award in writing and, unless all Parties agree otherwise, will include an
explanation in reasonable detail of the reasons for their award. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof, including in the courts described in Section 10.5. The arbitrators
will have the authority to grant injunctive relief and other specific performance; provided that the arbitrators will have no authority to award damages in contravention of this Agreement, and each Party irrevocably waives any claim to such damages
in contravention of this Agreement. The arbitrators will, in rendering their decision, apply the substantive law of the State of Delaware, without giving effect to conflict of law provisions that may require the application of the laws of another
jurisdiction. The decision and award rendered by the arbitrators will be final and non-appealable (except for an alleged act of corruption or fraud on the part of the arbitrator). 

10.6.5 The Parties shall use their reasonable efforts to conduct all dispute resolution procedures under this Agreement as expeditiously,
efficiently, and cost-effectively as possible. 
 10.6.6 All expenses and fees of the arbitrators and expenses for hearing facilities and
other expenses of the arbitration will be borne equally by the Parties unless the Parties agree otherwise or unless the arbitrators in the award assess such expenses against one of the Parties or allocate such expenses other than equally between the
Parties. Each of the Parties will bear its own counsel fees and the expenses of its witnesses except to the extent otherwise provided in this Agreement or by applicable law. 

  

					
		  	26	  	*Confidential Treatment Requested.

 10.6.7 Compliance with this Section 10.6 is a condition precedent to seeking relief in any
court or tribunal in respect of a dispute, but nothing in this Section 10.6 will prevent a Party from seeking equitable or other interlocutory relief in the courts of appropriate jurisdiction, pending the arbitrators’ determination of the
merits of the controversy, if applicable to protect the confidential information, property, or other rights of that Party or to otherwise prevent irreparable harm that may be caused by the other Party’s actual or threatened breach of this
Agreement. 
 10.7 No Discrimination. Licensee, its Affiliates, and any Sublicensees, in their respective activities under this
Agreement, shall not discriminate against any employee or applicant for employment because of race, color, sex, sexual, or affectional preference, age, religion, national, or ethnic origin, handicap, or because he or she is a disabled veteran or a
veteran (including a veteran of the Vietnam Era). 
 10.8 Compliance with Law. Licensee (and its Affiliates’ and any
Sublicensees’) must comply with all prevailing laws, rules, and regulations that apply to its activities or obligations under this Agreement. Without limiting the foregoing, it is understood that this Agreement may be subject to United States
laws and regulations controlling the export of technical data, computer software, laboratory prototypes, and other commodities, articles, and information, including the Arms Export Control Act as amended in the Export Administration Act of 1979 and
that Licensee’s obligations are contingent upon compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States
Government and/or written assurances by Licensee that Licensee shall not export data or commodities to certain foreign countries without prior approval of such agency. Licensor neither represents that a license is not required nor that, if required,
it will issue. 
 10.9 Entire Agreement. This Agreement embodies the entire understanding between the Parties relating to the subject
matter hereof and supersedes all prior understandings and agreements, whether written or oral, including that certain Mutual Non-Disclosure Agreement between the Parties dated December 3, 2012 . All “Confidential Information”
disclosed by the Parties pursuant to such Mutual Non-Disclosure Agreement shall be deemed “Confidential Information” under this Agreement (unless and until it falls within one of the exclusions set forth in Section 1.5). This
Agreement may not be varied except by a written document signed by duly authorized representatives of both Parties. 
 10.10 Marking.
Licensee, its Affiliates, and any Sublicensees shall mark any Licensed Product (or their containers or labels) made, sold, or otherwise distributed by it or them with any notice of patent rights necessary or desirable under applicable law to enable
the Licensed Patents to be enforced to their full extent in any country where Licensed Products are made, used, sold, offered for sale, or imported. 

10.11 Severability and Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent
jurisdiction, then such invalid or unenforceable provision will be automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the Parties’ original intent; provided that, if the Parties cannot agree
upon such valid or enforceable provision, the remaining provisions of this Agreement will remain in full force and effect, unless the invalid or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably
assumed that the Parties would not have entered into this Agreement without the invalid or unenforceable provisions. 

  
 27 

 10.12 Further Assurances. Each Party hereto agrees to execute, acknowledge, and deliver
such further instruments, and to do all other acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

10.13 Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only for
convenience of reference and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the word “including” shall be
deemed to be followed by the phrase “without limitation” or like expression; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine, and neuter pronouns and expressions shall
be interchangeable; (d) the words “herein” or “hereunder” relate to this Agreement; (e) “or” is disjunctive but not necessarily exclusive; (f) the word “will” shall be construed to have the same
meaning and effect as the word “shall”; (g) all references to “dollars” or “$” herein shall mean U.S. Dollars; (h) unless otherwise provided, all reference to Sections and exhibits in this Agreement are to
Sections and exhibits of and in this Agreement; and (i) whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified. Business days shall mean a day on which banking
institutions in Washington, D.C. are open for business. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and
applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

10.14 Cumulative Rights and Remedies. The rights and remedies provided in this Agreement and all other rights and remedies available to
either Party at law or in equity are, to the extent permitted by law, cumulative and not exclusive of any other right or remedy now or hereafter available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the
concurrent assertion of any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy. 

10.15 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of
which together will constitute one and the same instrument. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 28 

 IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this License
Agreement to be executed by their duly authorized representatives. 
  
  

									
	REGENX BIOSCIENCES, LLC	 		 	AUDENTES THERAPEUTICS, INC.
					
	By:	 	 /s/ Kenneth T. Mills
	 		 	By:	 	 /s/ Matthew Patterson

	Name:	 	Kenneth T. Mills	 		 	Name:	 	Matthew Patterson
	Title:	 	President & CEO	 		 	Title:	 	President & CEO

 Exhibit A 

Licensed Patents 
 Part
1, Licensed AAVS Patents 
  

									
	 Application #
	  	 Patent #
	  	 Filing Date*
	  	 Country
	  	 Status

	[*]	  	[*]	  	[*]	  	[*]	  	[*]

  

	*	International Filing Date, where national stage application or foreign divisional thereof 

Part 2, Licensed AAV9 Patents 
  

									
	 Application #
	  	 Patent #
	  	 Filing Date
	  	 Country
	  	 Status

	[*]	  	[*]	  	[*]	  	[*]	  	[*]

  

					
		  		  	*Confidential Treatment Requested.

 Exhibit B 

Press Release 
  

 
 REGENX Biosciences and Audentes Therapeutics Enter into Exclusive License Agreement for 

Development of Treatments for Serious, Rare Muscle Diseases Using NAVTM Vectors 

WASHINGTON & SAN FRANCISCO—(BUSINESS WIRE)—REGENX Biosciences, LLC and Audentes Therapeutics, Inc. announce that they have entered into an
agreement for the development and commercialization of products to treat X-Linked Myotubular Myopathy (XLMTM) and Pompe disease using NAV vectors. 

Under the terms of the Agreement, REGENX granted Audentes an exclusive worldwide license, with rights to sublicense, to REGENX’s NAV rAAV8 and
rAAV9 vectors for treatment of XLMTM and Pompe disease in humans. In return for these rights, REGENX receives an up-front payment, certain milestone fees and royalties on net sales of products incorporating NAV rAAV8 and rAAV9. 

“We believe this exclusive license agreement is important to the successful development of NAV-based gene delivery treatments for patients with XLMTM and
Pompe disease,” said Ken Mills, President and CEO of REGENX. “As a leader in gene therapy, we are pleased to be cooperating with the team at Audentes in its pursuit of developing innovative treatments for patients with serious, rare muscle
diseases through the application of NAV technology. REGENX has a continued interest to provide commercial partners that evidence outstanding leadership, expertise, resources and a strong commitment to patients, such as Audentes, with access
to our NAV technology.” 
 “Audentes is committed to the development of new treatments for patients with XLMTM and Pompe disease using AAV
gene therapy technology and we feel rAAV8 and rAAV9 are the most promising vectors to achieve this goal,” said Matthew R. Patterson, President and CEO of Audentes. “We are very pleased to enter into this agreement with REGENX, which we
believe offers us the best path to expeditiously develop novel therapies for patients.” 
 About X-Linked Myotubular Myopathy (XLMTM)

 X-Linked Myotubular Myopathy (XLMTM) is a rare, inherited disorder characterized by severe muscle weakness and respiratory impairment. It is
caused by mutations in the MTM1 gene, which encodes an enzyme called myotubularin. Myotubularin is thought to be involved in the development and maintenance of muscle cells. XLMTM affects approximately 1 in 50,000 newborn males worldwide. 

About Pompe Disease 
 Pompe Disease is a rare,
inherited disorder characterized by progressive muscle weakness and respiratory impairment. It is caused by mutations in a gene that encodes an enzyme called acid alpha-glucosidase (GAA), which is needed by the body to break down glycogen — a
stored form of sugar used for energy. Pompe Disease affects approximately 1 in every 40,000 births. 
 About REGENX Biosciences 

REGENX Biosciences is leading the effort to translate promising gene delivery applications into a pipeline of next generation personalized therapies for a
range of severe diseases with serious unmet needs. We believe that the NAV technology to which we have exclusive rights represents the potential promise of curing the root cause of disease rather than the symptoms, and we are committed to
establishing best in class standards for our NAV vectors. Our intent is to initially develop treatments for a number of rare, genetic diseases including hypercholesterolemias, the 

 
mucopolysaccharidoses, and retinitis pigmentosa and ensure continuing access for our NAV technology through innovative partnerships, license opportunities and the expansion of our growing
team of global collaborators. REGENX holds exclusive rights to a portfolio of over 100 patents and patent applications pertaining to its NAV technology and related applications. 

For more information regarding REGENX, please visit www regenxbio.com.  

About Audentes Therapeutics, Inc. 
 AudentesTM is a biotechnology company committed to the development and commercialization of innovative new treatments for people with serious, rare muscle diseases through the application of adeno-associated
virus (AAV) gene therapy technology. The company consists of a focused, experienced, and passionate team driven by the goal of improving the lives of patients. Audentes takes pride in strong, global relationships with the patient, research, and
medical communities. 
 For more information regarding Audentes, please visit www.audentestx corn.  

Contacts 
 REGENX Biosciences 

Vit Vasista, 202-785-7438 
 vvasista@regenxbio com 

or 
 Audentes Therapeutics, Inc. 

Matthew Patterson, 646-712-1001 
 mpatterson@audentestx.com 

  
 2 

 EXHIBIT C 

[*] 
 [9 pages omitted]

  

					
		  		  	*Confidential Treatment Requested.License Agreement (REGENXBIO - CPVT)

 EXHIBIT 10.16 
  

					
		  		  	 *  Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately
with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.

 LICENSE AGREEMENT 

This LICENSE AGREEMENT (“Agreement”) is entered into as of November 3, 2015 (“Effective Date”) by and between REGENXBIO
Inc., a corporation organized under the laws of the State of Delaware, with offices at 9712 Medical Center Drive, Suite 100, Rockville, MD 20850 (“Licensor”), and Audentes Therapeutics, Inc., a corporation organized under the laws
of the State of Delaware, with offices at 101 Montgomery Street, Suite 2650, San Francisco, California, 94104 (“Licensee”). Licensor and Licensee are hereinafter referred to individually as a “Party” and
collectively as the “Parties.” 
 WHEREAS, Licensor has rights under certain Licensed Patents (as defined herein) pertaining to certain
recombinant adeno-associated virus serotype 9 vectors; and 
 WHEREAS, Licensee desires to obtain an exclusive license under the Licensed Patents under the
terms set forth herein; 
 NOW, THEREFORE, in consideration of the promises and covenants contained in this Agreement, and intending to be legally bound,
the Parties hereby agree as follows: 
 ARTICLE 1: DEFINITIONS 

1.1”AAV9” means (a) the recombinant adeno-associated virus serotype 9 vector with the specified sequence set forth in GenBank [*] and
(b) any recombinant adeno-associated virus derivatives of such serotype 9 vector that are covered by the claims of the Licensed Patents. 
 1.2
“Additional Disease Indication” means one or more, or all of the inherited arrhythmias listed in Exhibit B and any Other Monogenetic Inherited Arrhythmia. 

1.3 “Additional Indication Option” has the meaning set forth in Section 2.3.1. 

1.4 “Additional Indication Term” means the period beginning on the Effective Date and ending on the second anniversary of the Effective Date.

 1.5 “Affiliate” means any legal entity directly or indirectly, during the term of this Agreement, controlling, controlled by, or under
common control with another entity. For purposes of this Agreement, “control” means the direct or indirect ownership of more than 50% of the outstanding voting securities of a legal entity, or the right to receive more than 50% of the
profits or earnings of a legal entity, or the right to control the policy decisions of a legal entity. An entity may be or become an Affiliate of an entity and may cease to be an Affiliate of an entity, in each case, during the term of this
Agreement. 
 *Confidential Treatment Requested. 

 CONFIDENTIAL 
  

1.6 “Calendar Quarter” means each three-month period or any portion thereof, beginning on January 1, April 1, July 1,
and October 1. 
 1.7 “Change of Control” means (i) any transaction or series of related transactions following which the holders
of Licensee’s capital stock or membership or equity interests immediately prior to such transaction or series of related transactions collectively are the owners of less than 50% of the outstanding equity interests of Licensee entitled to
(a) vote with respect to the election of directors (or positions having a similar function) or (b) receive the proceeds upon any sale, liquidation or dissolution of Licensee; (ii) a sale, transfer, or other disposition, in a single
transaction or series of related transactions, of all or a material portion of Licensee’s interest in the Licensed Product; (iii) a sale, transfer, or other disposition, in a single transaction or series of related transactions, of all or
a material portion of Licensee’s right, title, or interest in its assets taken as a whole, (iv) an initial public offering of the stock of Licensee; or (v) the merger of Licensee with a Third Party by operation of law or otherwise.

 1.8 “Commercial Field” means (a) CPVT Field unless and until a Substitution Option is exercised, subject to Section 2.2;
(b) if and when a Substitution Indication Option is exercised for an Additional Disease Indication by Licensee under Section 2.2, the treatment of such Additional Disease Indication in human beings by in vivo gene therapy with AAV9;
and, additionally, (c) if and when an Additional Indication Option is exercised for an Additional Disease Indication by Licensee under Section 2.3, the treatment of such Additional Disease Indication in human beings by in vivo gene
therapy with AAV9. 
 1.9 “Confidential Information” means and includes all technical information, inventions, developments, discoveries,
software, know-how, methods, techniques, formulae, animate and inanimate materials, data, processes, finances, business operations or affairs, and other proprietary ideas, whether or not patentable or copyrightable, of either Party that are
(a) marked or otherwise identified as confidential or proprietary at the time of disclosure in writing; or (b) if disclosed orally, visually, or in another non-written form, identified as confidential at the time of disclosure and
summarized in reasonable detail in writing as to its general content within 30 days after original disclosure. The Parties acknowledge that (i) the terms and conditions of this Agreement will be deemed the Confidential Information of both
Parties and (ii) the records and reports referred to in Section 3.7 will be deemed the Confidential Information of Licensee, regardless of whether such information is marked or identified as confidential. In addition, information provided
to Licensee pursuant to the provisions of Section 7.1 will be deemed the Confidential Information of Licensor, regardless of whether such information is marked or identified as confidential. Notwithstanding the foregoing, Confidential
Information will not include the following, in each case, to the extent evidenced by competent written proof of the Receiving Party: 
 1.9.1
information that was already known to the Receiving Party, other than under an obligation of confidentiality, at the time of disclosure by the Disclosing Party; 

  
 2 

 CONFIDENTIAL 
  

1.9.2 information that was generally available to the public or otherwise part of the public domain at the time of its disclosure to the
Receiving Party; 
 1.9.3 information that became generally available to the public or otherwise part of the public domain after its
disclosure, other than through any act or omission of the Receiving Party in breach of this Agreement; 
 1.9.4 information that is
independently discovered or developed by the Receiving Party without the use of Confidential Information of the Disclosing Party; or 
 1.9.5
information that was disclosed to the Receiving Party, other than under an obligation of confidentiality, by a Third Party who had no obligation to the Disclosing Party not to disclose such information to others. 

1.10 “CPVT Field” means the treatment of [*] catecholaminergic polymorphic ventricular tachycardia (“CPVT”) in human beings by in
vivo gene therapy with AAV9. 
 1.11 “Development Plan” has the meaning set forth in Section 4.2.1. 

1.12 “Disclosing Party” has the meaning set forth in Section 5.1. 

1.13 “Disease Indication(s)” means one or more, or all of the following: (i) [*] CPVT, (ii) one or more, or all of the inherited
arrhythmias listed in Exhibit B, and (iii) any Other Monogenetic Inherited Arrhythmia. 
 1.14 “Domain Antibody” means [*]. 

1.15 “FDA” means the United States Food and Drug Administration, or a successor agency in the United States with responsibilities comparable
to those of the United States Food and Drug Administration. 
 1.16 “GSK Agreement” means that certain License Agreement entered into
between Licensor and SmithKline Beecham Corporation, effective on March 6, 2009, as amended by that certain Amendment to License Agreement dated April 15, 2009, and as amended from time to time. 

1.17 “Licensed Patents” means, to the extent they cover AAV9, (a) all United States patents and patent applications listed in Exhibit
A, including patents arising from such patent applications and (b) any re-examination certificates thereof, (c) the foreign counterparts of the patents and patent applications in subsections (a) and (b), and (d) extensions,
continuations, divisionals, and re-issue applications of the patents and patent applications in subsections (a), (b) and (c); provided that “Licensed Patents will not include any claim of a patent or patent application covering
“Manufacturing Technology” which is owned or controlled by Licensor. 
 1.18 “Licensed Product” means (a) any AAV9 product
that is made, made for, used, sold, offered for sale, or imported by Licensee, its Affiliates, and any of its or their Sublicensees, the manufacture, use, sale, offer for sale, or import of which product, in the absence of the license granted
pursuant to this Agreement, would infringe or is covered by at least one Valid Claim of the Licensed Patents in the country of manufacture, use, sale, offer for sale, or import, including 

  

					
		  	3	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

products manufactured by a process that would infringe or is covered by at least one Valid Claim of the Licensed Patents in the country of manufacture, use,
sale, offer for sale, or import; or (b) any service sold by Licensee, its Affiliates, and any of its or their Sublicensees with respect to the administration of any AAV9 product to patients that, in the absence of the licenses granted pursuant
to this Agreement, would infringe or is covered by at least one Valid Claim of the Licensed Patents in the country of sale. 
 1.19 “Licensee
Inventions” means any new or improved composition of matter, process, method, formula, information, product, invention (whether or not patentable or otherwise protectable), discovery, idea, material, or other know-how that is first
discovered, produced, conceived, or reduced to practice by or on behalf of Licensee, its Affiliates, or any of its or their Sublicensees during the term of the Agreement in connection with the exercise of any rights granted under this Agreement that
relate to or are applicable to the inventions claimed in the Licensed Patents; provided that any new or improved process, method, formula, information, invention (whether or not patentable or otherwise protectable), discovery, idea, or other
know-how solely to the extent that it covers Manufacturing Technology shall not be included in Licensee Inventions. 
 1.20 “Manufacturing
Technology” means any and all patents, patent applications, know-how, and all intellectual property rights associated therewith, and including all tangible embodiments thereof, that are claim, cover or relate to the manufacture of
adeno-associated viruses, adeno-associated virus vectors, research or commercial reagents related thereto, Licensed Products, or other products, including manufacturing processes, technical information relating to the methods of manufacture,
protocols, standard operating procedures, batch records, assays, formulations, quality control data, specifications, scale up methods, any and all improvements, modifications, and changes thereto, and any and all activities associated with such
manufacture. Any and all chemistry, manufacturing, and controls (CMC), drug master files (DMFs), or similar materials provided to regulatory authorities and the information contained therein are deemed Manufacturing Technology. 

1.21 “Marketing Authorization” means all approvals, licenses, registrations or authorizations of any federal, state or local regulatory
agency, department, bureau or other governmental entity, necessary for the manufacturing, use, storage, import, transport, marketing and sale of Licensed Products in a country or regulatory jurisdiction. 

1.22 “Other Monogenetic Inherited Arrhythmias” means monogenetic inherited arrhythmias that are not listed in Exhibit B; provided that the
treatment of such monogenetic inherited arrhythmias would not involve the use of AAV9 to deliver any and all genes encoding I-1c, Serca2a and creatine kinase. For purposes of clarity, the treatment of monogenetic inherited arrhythmias that would
involve the use of AAV9 to deliver any and all genes encoding I-1c, Serca2a and creatine kinase are not included in the definition of Other Monogenetic Inherited Arrhythmias. 

1.23 “NDA” means a New Drug Application filed with the FDA as described in 21 C.F.R. § 314, a Biological License Application (BLA)
pursuant to 21 C.F.R. § 601.2, or any equivalent or any corresponding application for regulatory approval in any country or regulatory jurisdiction other than the United States. 

  
 4 

 CONFIDENTIAL 
  

1.24 “Net Sales” means the gross receipts from sales or other disposition of a Licensed Product (including fees for services within the
definition of “Licensed Product”) by Licensee and/or its Affiliates and/or any Sublicensees to Third Parties less the following deductions that are directly attributable to a sale, specifically and separately identified on an invoice or
other documentation and actually borne by Licensee, its Affiliates, or any Sublicensees: [*] In the event consideration other than cash is paid to Licensee, its Affiliates, or any Sublicensees, for purposes of determining Net Sales, the Parties
shall use the cash consideration that Licensee, its Affiliates, or any Sublicensees would realize from an unrelated buyer in an arm’s length sale of an identical item sold in the same quantity and at the time and place of the transaction, as
determined jointly by Licensor and Licensee based on transactions of a similar type and standard industry practice, if any. 
 1.25 “Penn
Agreement” means that certain License Agreement entered into between Licensor and The Trustees of the University of Pennsylvania, effective on February 24, 2009, as amended by that letter agreement dated March 6, 2009 and by that
certain Second Amendment to License Agreement effective on September 9, 2014, and as amended from time to time. 
 1.26 “Phase 3 Clinical
Trial” means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to
evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in
jurisdictions other than the United States. 
 1.27 “Prosecute” means preparation, filing, and prosecuting patent applications and
maintaining patents, including any reexaminations, reissues, oppositions, inter partes review, and interferences. 
 1.28 “Receiving Party”
has the meaning set forth in Section 5.1. 
 1.29 “REGENXBIO Licensors” means SmithKline Beecham Corporation (or any successor thereto
under the GSK Agreement) and The Trustees of the University of Pennsylvania (or any successor thereto under the Penn Agreement). 
 1.30 “Restricted
Field” means, collectively, (a) the Commercial Field, (b) the treatment of Crigler-Najjar syndrome in humans by in vivo gene therapy using AAV8, (c) the treatment of X-linked myotubular myopathy (XLMTM) in humans by
in vivo gene therapy in humans using AAV8 or AAV9, and (d) the treatment of Pompe Disease (GAA deficiency) in humans by in vivo gene therapy in humans using AAV8 or AAV9. 

1.31 “Retained Rights” has the meaning set forth in Section 2.4. 

1.32 “Sublicensee” means (i) any Third Party or Affiliate to whom Licensee grants a sublicense of some or all of the rights granted to
Licensee under this Agreement as permitted by this Agreement; and (ii) any other Third Party or Affiliate to whom a sublicensee described in clause (i) has granted a further sublicense as permitted by this Agreement. 

1.33 “Substitution Indication Option” has the meaning set forth in Section 2.2.1. 

  

					
		  	5	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

1.34 “Substitution Indication Term” means the period beginning on the Effective Date and ending on the earlier of (i) Licensor’s
second exercise of the Substitution Indication Option, and (ii) the second anniversary of the Effective Date. 
 1.35 “Third Party”
means any person or entity other than a Party to this Agreement or Affiliates of a Party to this Agreement. 
 1.36 “Valid Claim” means a
claim of an issued and unexpired patent (including any patent claim the term of which is extended by any extension, supplementary protection certificate, patent term restoration, or the like) included within the Licensed Patents or a claim of a
pending patent application included within the Licensed Patents, which has not lapsed, been abandoned, been held revoked, or been deemed unenforceable or invalid by a non-appealable decision or an appealable decision from which no appeal was taken
within the time allowed for such appeal of a court or other governmental agency of competent jurisdiction. 
 ARTICLE 2: LICENSE GRANTS

 2.1 Exclusive License Grant. Subject to the terms and conditions of this Agreement, including the Retained Rights, Licensor hereby grants to
Licensee an exclusive, sublicensable (as provided in Section 2.6 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license under the Licensed Patents to make, have made, use, import, sell, and offer
for sale Licensed Products in the CPVT Field, including, for the avoidance of doubt, the right to conduct research and development, unless and until a Substitution Indication Option is exercised. 

2.2 Substitution Indication License Option. 

2.2.1 Option. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee the option, exercisable at
Licensee’s sole discretion, to cease development of Licensed Products for use in the CPVT Field and to obtain an exclusive, sublicensable (as provided in Section 2.6), non-transferable (except as provided in Section 10.2),
royalty-bearing, worldwide license with respect to Licensed Products for a single Additional Disease Indication for which Licensee has not exercised Licensee’s Additional Indication Option under Section 2.3, in accordance with the
provisions below in this Section 2.3.2. After Licensee elects to substitute a single Additional Disease Indication for [*] CPVT, Licensee shall have the option, exercisable at Licensee’s sole discretion, to cease development of Licensed
Products for use with respect to such single Additional Disease Indication and to obtain an exclusive, sublicensable (as provided in Section 2.6), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license
with respect to Licensed Products for another Additional Disease Indication for which Licensee has not exercised Licensee’s Additional Indication Option under Section 2.3, in accordance with the provisions below in this Section 2.2.
Each of the two substitution options permitted in this Section 2.2 shall be referred to as the “Substitution Indication Option.” 

2.2.2 Method of Exercise. To exercise the Substitution Indication Option for a particular Additional Disease Indication, Licensee must
provide written notice to Licensor of an Additional Disease Indication for inclusion in the Commercial Field under this Agreement prior to the end of the Substitution Indication Term. Within [*] of Licensor’s receipt of such 

  

					
		  	6	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

nomination, Licensor will inform Licensee in writing whether the nominated Additional Disease Indication is available for licensing based on whether it:
(a) is the subject of a conflicting license with a Third Party (or the subject of a license being negotiated with a Third Party, as to which (i) there has been a written request for license terms from such Third Party, (ii) such Third
Party or Licensor has submitted a written proposal for terms for a license (which may be limited to financial terms), (iii) Licensor and such Third Party have entered into a confidentiality agreement for purposes of such Third Party conducting
a due diligence review, and (iv) a “writing” for purposes of the foregoing clauses includes e-mail correspondence); or (b) is part of an existing Licensor program (i.e., a program that is the subject of on-going advanced
preclinical study (e.g., there has been a pre-IND meeting) or is in clinical development or at a later stage of development or commercialization). If the nominated Additional Disease Indication is subject to a conflicting Third Party license or a
license being negotiated with a Third Party, or subject to an existing Licensor program, then the Additional Disease Indication may be rejected upon written notice by Licensor to Licensee; provided that Licensor will notify Licensee if Licensor does
not enter into an agreement with the relevant Third Party within [*] after rejecting such Additional Disease Indication, in which case Licensee shall have the right again to nominate such Additional Disease Indication pursuant to this
Section 2.2.2. Otherwise, the Additional Disease Indication will be deemed available for licensing and Licensor shall provide written confirmatory notice to Licensee. 

2.2.3 License Grant Upon Exercise. If Licensee exercises the Substitution Indication Option for a particular Additional Disease
Indication, effective upon Licensor’s receipt of the notice described in Section 2.2.2 (the “Substitution Grant Date” for such Additional Disease Indication), subject to the terms and conditions of this Agreement,
including the Retained Rights, Licensor shall be deemed to have granted to Licensee an exclusive, sublicensable (as provided in Section 2.6 only), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license
under the Licensed Patents to make, have made, use, import, sell, and offer for sale Licensed Products in the Commercial Field of such Additional Disease Indication, including, for the avoidance of doubt, the right to conduct research and
development. For avoidance of doubt, the license granted pursuant to this Section 2.2.3 will be deemed granted on the Substitution Grant Date with respect to a particular Additional Disease Indication, solely with respect to the Commercial
Field associated with Additional Disease Indication for which the Substitution Indication Option was exercised under this Section 2.2 and solely with respect to Licensed Products for the particular Additional Disease Indication. 

2.3 Additional Indication License Option. 

2.3.1 Option. Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee a non-exclusive option,
exercisable at Licensee’s sole discretion, to obtain an exclusive, sublicensable (as provided in Section 2.6), non-transferable (except as provided in Section 10.2), royalty-bearing, worldwide license with respect to each of the
Additional Disease Indications and AAV9 (each such right with respect to a particular Additional Disease Indication, a “Additional Indication Option”) in accordance with the following provisions: 

2.3.2 Method of Exercise. To exercise the Additional Indication Option for a particular Additional Disease Indication, Licensee may
nominate in writing to Licensor an Additional Disease Indication for inclusion in the Commercial Field under this Agreement prior to the end 

  

					
		  	7	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

of the Additional Indication Term. Within [*] of Licensor’s receipt of such nomination, Licensor will inform Licensee in writing whether the nominated
Additional Disease Indication is available for licensing based on whether it: (a) is the subject of a conflicting license with a Third Party (or the subject of a license being negotiated with a Third Party, as to which (i) there has been a
written request for license terms from such Third Party, (ii) such Third Party or Licensor has submitted a written proposal for terms for a license (which may be limited to financial terms), (iii) Licensor and such Third Party have entered
into a confidentiality agreement for purposes of such Third Party conducting a due diligence review, and (iv) a “writing” for purposes of the foregoing clauses includes e-mail correspondence); or (b) is part of an existing
Licensor program (i.e., a program that is the subject of on-going advanced preclinical study (e.g., there has been a pre-IND meeting) or is in clinical development or at a later stage of development or commercialization). If the nominated Additional
Disease Indication is subject to a conflicting Third Party license or subject to an existing Licensor program, then the Additional Disease Indication may be rejected upon written notice by Licensor to Licensee, provided that Licensor will notify
Licensee if Licensor does not enter into an agreement with the relevant Third Party within [*] after rejecting such Additional Disease Indication, in which case Licensee shall have the right again to nominate such Additional Disease Indication
pursuant to this Section 2.3.2. Otherwise, the Additional Disease Indication will be deemed available for licensing and Licensor shall provide written confirmatory notice to Licensee. Upon Licensee’s receipt of Licensor’s confirmatory
written notice that the Additional Disease Indication is available for licensing, Licensee will wire transfer to Licensor the option fee set forth in Section 3.2. 

2.3.3 License Grant Upon Exercise. If Licensee exercises the Additional Indication Option for a particular Additional Disease Indication
by providing the written notice described in Section 2.3.2, effective upon Licensor’s receipt of the fee described in Section 2.3.2 (the “Grant Date” for such Additional Disease Indication), subject to the terms and
conditions of this Agreement, including the Retained Rights, Licensor shall be deemed to have granted to Licensee an exclusive, sublicensable (as provided in Section 2.6 only), non-transferable (except as provided in Section 10.2),
royalty-bearing, worldwide license under the Licensed Patents to make, have made, use, import, sell, and offer for sale Licensed Products in the Commercial Field of such Additional Disease Indication, including, for the avoidance of doubt, the right
to conduct research and development. 
 2.3.4 Additional Disease Indications. For the avoidance of doubt, the foregoing license
granted pursuant to Section 2.3.3 will be deemed granted on the Grant Date on an Additional Disease Indication-by-Additional Disease Indication basis, solely with respect to the Commercial Field associated with the Additional Disease Indication
for which the Additional Indication Option was exercised under this Section 2.3 and solely with respect to Licensed Products for the particular Additional Disease Indication. The Parties acknowledge that there may be different Grant Dates for
each Additional Disease Indication, depending on when and if Licensee exercises the Additional Indication Option for a particular Additional Disease Indication. As set forth above, Licensee, at its sole discretion, may exercise the Additional
Indication Option with respect to any or all of the Additional Disease Indications. The Additional Indication Option will terminate with respect to unexercised Additional Disease Indications at the end of the Additional Indication Term (together
with the license granted under Section 2.3.3), and Licensee will have no further rights under this Agreement with respect to the unexercised Additional Disease Indications; provided that the termination of the Additional Indication Option will
not affect Licensee’s rights under this Agreement with respect to the license granted under Section 2.1, and if applicable Section 2.2.3. 

  

					
		  	8	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

2.4 Retained Rights. 
 2.4.1 Except for the
rights and licenses specified in Section 2.1 and, if applicable, Sections 2.2.3 and 2.3.3, no license or other rights are granted to Licensee under any intellectual property of Licensor, whether by implication, estoppel, or otherwise and
whether such intellectual property is subordinate, dominant, or otherwise useful for the practice of the Licensed Patents. Notwithstanding anything to the contrary in this Agreement, Licensor may use and permit others to use the Licensed Patents for
any research, development, commercial, or other purposes inside or outside of the Commercial Field (other than to the extent of the exclusive license under Section 2.1 and if applicable, Sections 2.2.3 and 2.3.3). Without limiting the
foregoing, and notwithstanding anything in this Agreement to the contrary, Licensee acknowledges and agrees to the following rights retained by Licensor and the REGENX Licensors (individually and collectively, the “Retained
Rights”), whether inside or outside the Commercial Field: 
 2.4.1.1 The rights and licenses granted in
Section 2.1 and, if applicable, Sections 2.2.3 and 2.3.3 shall not include any right (and Licensor and the REGENX Licensors retain the exclusive (even as to Licensee), fully sublicensable right) under the Licensed Patents to make, have made,
use, sell, offer to sell, and import Domain Antibodies that are expressed by an adeno-associated vector, including AAV9. 

2.4.1.2 The rights and licenses granted in Section 2.1 and, if applicable, Sections 2.2.3 and 2.3.3 shall not include any
right (and Licensor and the REGENX Licensors retain the exclusive (even as to Licensee), fully sublicensable right) under the Licensed Patents to make, have made, use, sell, offer to sell, and import Licensed Products for the treatment of
(i) congestive heart failure suffered by Muscular Dystrophy patients and (ii) any and all cardiovascular diseases by delivery of any or all of genes encoding I-1c and Serca2a and creatine kinase. 

2.4.1.3 Licensor and the REGENX Licensors retain the following rights with respect to the Licensed Patents: 

 

	 	(a)	A non-exclusive, sublicensable right under the Licensed Patents to make, have made, use, sell, offer to sell, and import products that deliver RNA interference and antisense drugs using an adeno-associated vector,
including AAV9; 

  

	 	(b)	A non-exclusive right for the REGENX Licensors (which right is sublicensable by such licensors) to use the Licensed Patents for non-commercial research purposes and to use the Licensed Patents for such licensors’
discovery research efforts with non-profit organizations and collaborators; and 

  

	 	(c)	A non-exclusive, sublicensable right under the Licensed Patents to make, have made, and use an adeno-associated vector, including AAV9, for non-commercial research in the area of congestive heart failure suffered by
Muscular Dystrophy patients and other cardiovascular disease. 

  
 9 

 CONFIDENTIAL 
  

2.4.1.4 The rights and licenses granted in Section 2.1 and, if applicable, Sections 2.2.3 and 2.3.3 shall not include any
right (and Licensor retains the exclusive (even as to Licensee), fully sublicensable right) under the Licensed Patents: 
  

	 	(a)	to conduct commercial reagent and services businesses, which includes the right to make, have made, use, sell, offer to sell, and import research reagents, including any viral vector construct; provided that, for
clarity, the foregoing retained right does not give Licensor the right to conduct clinical trials in humans in the Commercial Field using AAV9; or 

  

	 	(b)	to use the Licensed Patents to provide services to any Third Parties; provided that Licensee’s license under Section 2.1 and, if applicable, Sections 2.2.3 and 2.3.3 does include the right to provide services
in connection with the administration of Licensed Products to patients. 

 2.4.1.5 Licensor retains the fully
sublicensable right under the Licensed Patents to grant non-exclusive research and development licenses to Affiliates and Third Parties; provided that such development rights granted by Licensor shall not include the right to conduct clinical trials
in humans in the Commercial Field using AAV9 or any rights to sell products using AAV9 in the Commercial Field. 
 2.4.1.6
The Trustees of the University of Pennsylvania may use and permit other non-profit organizations or other non-commercial entities to use the Licensed Patents for educational and research purposes. 

2.5 Government Rights. Licensee acknowledges that the United States government retains certain rights in intellectual property funded in whole or part
under any contract, grant, or similar agreement with a federal agency. The license grants hereunder are expressly subject to all applicable United States government rights, including any applicable requirement that products that result from such
intellectual property and are sold in the United States must be substantially manufactured in the United States. 
 2.6 Sublicensing. 

2.6.1 The license granted pursuant to Section 2.1 and, if applicable, Sections 2.2.3 and 2.3.3 is sublicensable by Licensee to any
Affiliates or Third Parties [*]; provided that any such sublicense must comply with the provisions of this Section 2.6 (including Section 2.6.2). 

2.6.2 The right to sublicense granted to Licensee under this Agreement is subject to the following conditions: 

 

	 	(a)	Licensee may only grant sublicenses pursuant to a written sublicense agreement with the Sublicensee Licensor must receive written notice as soon as practicable following execution of any such sublicenses. Any further
sublicenses granted by any Sublicensee (to the extent permitted hereunder) must comply with the provisions of this Section 2.6 (including Section 2.6.2) to the same extend as if Licensee granted such sublicense directly. 

  

					
		  	10	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

 

	 	(b)	In each sublicense agreement, the Sublicensee must be required to comply with the applicable terms and conditions of this Agreement to the same extent as Licensee has agreed and must acknowledge that Licensor is an
express third party beneficiary of such terms and conditions under such sublicense agreement. 

  

	 	(c)	The official language of any sublicense agreement shall be English. 

  

	 	(d)	Within [*] after entering into a sublicense, Licensor must receive a copy of the sublicense written in the English language for Licensor’s records and to share with the REGENX Licensors. The copy of the sublicense
may be redacted to exclude confidential information of the applicable Sublicensee, but such copy shall not be redacted to the extent that it impairs Licensor’s (or the REGENX Licensors’) ability to ensure compliance with this Agreement;
provided that, if either of the REGENX Licensors requires a complete, unredacted copy of the sublicense, Licensee shall provide such complete, unredacted copy. 

  

	 	(e)	Licensee’s execution of a sublicense agreement will not relieve Licensee of any of its obligations under this Agreement. Licensee is and shall remain [*] to Licensor for all of Licensee’s duties and
obligations contained in this Agreement and for any act or omission of an Affiliate or Sublicensee that would be a breach of this Agreement if performed or omitted by Licensee, and Licensee will be deemed to be in breach of this Agreement as a
result of such act or omission. 

 2.7 Non-Exclusive License Under Licensee Inventions. Licensee hereby grants to Licensor a
non-exclusive, worldwide, royalty-free, transferable, sublicensable, irrevocable, perpetual license under Licensee Inventions to practice the Licensee Inventions in connection with AAV9 outside of the Restricted Field, including, for avoidance of
doubt, the right to conduct research and develop and commercialize products and services outside of the Restricted Field. 
 2.8 Improvements. 

2.8.1 Licensee hereby grants to Licensor a non-exclusive, worldwide, royalty-free, transferable, sublicensable, irrevocable, perpetual license:

  

	 	(a)	to use any Licensed Back Improvements (and any intellectual property rights with respect thereto) consummate in scope to the Retained Rights, and 

 

	 	(b)	to practice the Licensed Back Improvements (and any intellectual property rights with respect thereto) in connection with AAV9, including the right to research, develop, make, have made, use, offer for sale, and sell

	 	products and services; provided that Licensor shall have no right, under the license in this Section 2.8.1(b), to practice the Licensed Back Improvements in the Restricted Field. 

  

					
		  	11	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

2.8.2 For purposes of this Agreement, “Licensed Back Improvements” means any [*] to any vector that is the
subject of a claim within the Licensed Patents during the term of the Agreement, which improvements or modifications are developed by Licensee or any of its Affiliates during the term of this Agreement or by any Sublicensee during the term of any
sublicense agreement with such Sublicensee. 
 2.8.3 Licensee agrees to provide prompt notice to Licensor upon the filing of
any patent application covering any Licensee Inventions and/or any Licensed Back Improvement, together with a reasonably detailed description of or access to such Licensee Inventions and/or Licensed Back Improvement to permit the practice of any
such invention or improvement. For clarity, Licensee shall have no obligation under this Agreement to deliver to Licensor any tangible embodiments of the Licensee Inventions and/or Licensed Back Improvements, if any. 

2.9 Section 365(n) of the Bankruptcy Code. All rights and licenses granted to Licensee or Licensor under or pursuant to this Agreement are and will
otherwise be deemed to be, for purposes of Section 365(n) of the United States Bankruptcy Code (Title 11, U.S. Code), as amended (the “Bankruptcy Code”) or any comparable law outside the United States, licenses of rights to
“intellectual property” as defined in Section 101(35A) of the Bankruptcy Code. The Parties will retain and may fully exercise all of their respective rights and elections under the Bankruptcy Code and any comparable law outside the
United States. 
 ARTICLE 3: CONSIDERATION 

3.1 Upfront Fee. In partial consideration of the rights and licenses granted to Licensee under this Agreement, Licensee shall make the following
payment to Licensor: one million U.S. Dollars ($1,000,000) within five (5) days of the Effective Date. 
 3.2 Additional Indication Option Fee.
For each exercise by Licensee of an Additional Indication Option granted to Licensee under Section 2.3, Licensee shall pay Licensor a fee of five hundred thousand U.S. Dollars ($500,000) for the exercise of such option. 

3.3 Annual Maintenance Fee. In partial consideration of the rights and licenses granted to Licensee under this Agreement, Licensee shall pay Licensor
on-going annual maintenance fees on each anniversary of the Effective Date. The annual maintenance fees will be as follows: 
  

	 	(a)	[*] per Disease Indication in the Commercial Field until commencement of the first Phase 3 Clinical Trial for a Licensed Product; provided that the annual maintenance fee shall not exceed a total of [*] per year; and

  

	 	(b)	Upon and after commencement of the first Phase 3 Clinical Trial for a Licensed Product, then [*] per Disease Indication licensed; provided that the annual maintenance fee shall not exceed a total of [*] per year.

  

					
		  	12	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

3.4 Milestone Fees. 
 3.4.1 Development
Milestones. In partial consideration of the rights and licenses granted to Licensee under this Agreement, Licensee shall pay Licensor the following milestone payments on a per-Disease Indication basis for each Licensed Product to achieve such
milestone event: 
  

			
	 Milestone
	  	 Milestone Payment

	 1.      First treatment of human subject in a clinical trial (i.e., first patient, first
dose)
	  	[*] U.S. Dollars in the form of cash or equity consideration 
	 2.      First treatment in Phase 3 Clinical Trial (i.e., first patient, first dose)
	  	[*] U.S. Dollars
	 3.      NDA submission in the United States
	  	[*] U.S. Dollars
	 4.      Marketing Authorization submission in a country or territory other than the United
States
	  	[*] U.S. Dollars
	 5.      NDA approval in the United States
	  	[*] U.S. Dollars
	 6.      Marketing Authorization approval in a country or territory other than the United States
	  	[*] U.S. Dollars

 3.4.2 Net Sales Milestones. In partial consideration of the rights and licenses granted to
Licensee under this Agreement, Licensee shall pay Licensor the following milestone payments on the aggregate of Net Sales of all Licensed Products: 
  

			
	 First time annual aggregate Net Sales of all Licensed Products equals or exceeds $100,000,000 U.S. Dollars
	  	[*] U.S. Dollars
	 First time annual aggregate Net Sales of all Licensed Products equals or exceeds $500,000,000 U.S. Dollars
	  	[*] U.S. Dollars
	 First time annual aggregate Net Sales of all Licensed Products equals or exceeds $750,000,000 U.S. Dollars
	  	[*] U.S. Dollars

 3.4.3 For clarity, the milestone payments set forth in Section 3.4.1 are payable with respect to
each Licensed Product and for each Disease Indication in the Commercial Field that achieves the milestone event, regardless of whether the milestone is achieved by Licensee, any Affiliate, or any Sublicensee. However, if Licensee exercises its
Substitution Indication Option, Licensee shall not owe Licensor any milestone payments for Licensed Products for use in the substituted Additional Disease Indication that have been made to Licensor for the achievement 

  

					
		  	13	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

of the same milestone for Licensed Products for use in the CPVT Field or a previously substituted Additional Disease Indication. To the extent that either of
the first two development milestones in Section 3.4.1 (i.e., first treatment of a human subject in a clinical trial or first treatment in Phase 3 Clinical Trial in the applicable Disease Indication) has not been paid at the time of achievement
of either the NDA or Marketing Authorization submission milestone within the same Disease Indication (i.e., milestones 3 and 4 in Section 3.4.1), then, upon the achievement of either of such submission milestones, the preceding unpaid
development milestone payments within such Disease Indication shall be made in addition to the payment corresponding to the applicable submission milestone that has been achieved. 

3.5 Royalties. 
 3.5.1 In consideration of
the rights and licenses granted to Licensee under this Agreement, Licensee shall pay to Licensor the following royalties based upon the annual Net Sales worldwide of all Licensed Products in a given calendar year, subject to the reductions in
royalty rates set forth in Section 3.5.2: 
  

			
	 Cumulative Annual Net Sales of all Licensed

Products Worldwide
	  	 Royalty Percentage

	 Portion of Net Sales in a calendar year less than

$300,000,000 U.S. Dollars
	  	[*]%
	 Portion of Net Sales in a calendar year between

(and including) $300,000,000 U.S. Dollars

through (and including) $600,000,0000 U.S.

Dollars
	  	[*]%
	 Portion of Net Sales in a calendar year greater

than $600,000,000 U.S. Dollars
	  	[*]%

 3.5.2 Third Party Royalties Stacking Provision. If Licensee must obtain a license from a Third Party to
avoid infringement of such Third Party’s rights in order to manufacture, use, or commercialize a given Licensed Product and if the royalties required to be paid to such Third Party for such license, together with those royalties payable to
Licensor, in the aggregate, exceed [*] percent ([*]%) of Net Sales for any Licensed Product, then the royalty owed to Licensor for that Licensed Product will be reduced by an amount calculated as follows: 

STACKING ROYALTY CALCULATIONS 

R = (C * (A / (A+B))) 
 Where 

R = reduction of Licensor royalty, 

A = unreduced Licensor royalty, 
 B
= sum of all Third Party royalties, 
 C = increment of projected total royalty above [*]%. 

  

					
		  	14	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

Example Calculation: 
  

					
		 	Assume:	  	i) all Third Party royalties = [*]%
		 		  	ii) unreduced Licensor royalty = [*]%
		 		  	iii) projected total royalty = [*]%

  

			
		  	 R = ([*] – [*]) * ([*] / ([*] + [*]))
 R =
([*] * [*])
 R = [*]
 Licensor Stacked Royalty = [*] – [*]
= [*]%

 Notwithstanding the foregoing, Licensee will pay to Licensor no less than [*] percent ([*]%) of the
royalties that Licensee would otherwise pay to Licensor with respect to Net Sales if there were no royalties due to Third Parties. 

3.5.3 Royalty Payment Period. Licensee’s obligation hereunder for payment of a royalty under this Section 3.5 on the Net Sales
of Licensed Products in a given country will end on a Licensed Product-by-Licensed Product and country-by-country basis when the Licensed Product ceases to infringe or be covered by a Valid Claim within the Licensed Patents in that country. For
clarity, only one royalty, determined in accordance with this Section 3.5, is payable on the Net Sales of any unit of a Licensed Product. 
 3.6
Sublicense Fees & Priority Review Voucher Transfer Fee. 
 3.6.1 In further consideration of the rights and licenses granted
to Licensee under this Agreement, Licensee will pay Licensor [*] percent ([*]%) of any sublicense fees (including upfront and milestone payments) received by Licensee or its Affiliates for the Licensed Products from any Sublicensee or from any
person or entity granted any option to obtain a sublicense. 
 3.6.2 In further consideration of the rights and licenses granted to Licensee
under this Agreement, Licensee will pay Licensor [*] percent ([*]%) of the fees related to the sale or other transfer to a Third Party rights under any priority review voucher issued in connection with or otherwise related to a Licensed Product,
provided, however, that this clause shall not apply to any such sale or other transfer that is made in connection with a change of control of Licensee or its Affiliates. 

3.6.3 With respect to the obligations under this Section 3.6, Licensee shall not be required to submit any amounts received from a Third
Party for the following: 
  

	 	(a)	Reimbursement or payment of Licensee’s actual costs or on an arm’s length cost plus arrangement for research, development, and/or manufacturing activities performed by Licensee or its Affiliates corresponding
directly to the research, development and/or manufacturing of Licensed Products pursuant to a specific agreement; 

  

					
		  	15	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

 

	 	(b)	Any and all amounts paid to Licensee or its Affiliates by a Sublicensee as royalties (or other similar payments, e.g., profit share) on sales of Licensed Product sold by the Sublicensee under a sublicense
agreement; and 

  

	 	(c)	Consideration received for the purchase of an equity interest in Licensee or its Affiliates at fair market value or in the form of loans at arm’s length rates of interest. 

3.6.4 If Licensee or its Affiliates receives sublicense fees from Sublicensees or from any person or entity granted any option to obtain a
sublicense under this Agreement in the form of non-cash consideration, then Licensee shall pay Licensor a cash payment as required under this Section 3.6 determined based on the fair market value of such non-cash consideration. If Licensee or
its Affiliate enters into any sublicense that is not an arm’s length transaction, fees due under this Section 3.6 will be calculated based on the fair market value of such transaction, at the time of the transaction, assuming an arm’s
length transaction made in the ordinary course of business, as determined jointly by Licensor and Licensee based on transactions of a similar type and standard industry practice, if any. 

3.6.5 To the extent Licensee receives payment from a Third Party relating to one or more of the milestone events set forth in the table in
Section 3.4, then the amount of the payment made to Licensor under such Section 3.4 with respect to such milestone event shall not be deemed sublicense fees under this Section 3.6; instead, the amounts due under this Section 3.6
shall be calculated by applying the applicable sublicense fee rate set forth in Section 3.6.1 above to the sublicense fees received by Licensee from such Third Party after deducting the amount of the payment under Section 3.4. 

3.7 Reports and Records. 
 3.7.1 Licensee
must deliver to Licensor within [*] after the end of each Calendar Quarter after the first commercial sale of a Licensed Product a report setting forth the calculation of the royalties due to Licensor for such Calendar Quarter, including: 

 

	 	(a)	Number of Licensed Products included within Net Sales, listed by country; 

  

	 	(b)	Gross consideration for Net Sales of Licensed Product, including all amounts invoiced, billed, or received; 

  

	 	(c)	Qualifying costs to be excluded from the gross consideration, as described in Section 1.24, listed by category of cost; 

  

	 	(d)	Net Sales of Licensed Products listed by country; 

  

	 	(e)	A detailed accounting of any royalty reductions applied pursuant to Section 3.5.2; 

  

	 	(f)	Royalties owed to Licensor listed by category; and 

  

	 	(g)	The computations for any applicable currency conversions. 

  

					
		  	16	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

 
 3.7.2 Licensee shall pay the royalties due under Section 3.5 within
[*] following the last day of the Calendar Quarter in which the royalties accrue. Licensee shall send the royalty payments along with the report described in Section 3.7.1. 

3.7.3 Within [*] after the occurrence of a milestone event described in Section 3.4, Licensee must deliver to Licensor a report describing
the milestone event that occurred, together with a payment of the applicable amount due to Licensor pursuant to Section 3.4. 
 3.7.4
Within [*] after the receipt of any fees from any Sublicensee as described in Section 3.5, Licensee must deliver to Licensor a report describing the fees received, together with a payment of the applicable amount due to Licensor pursuant to Section
3.6. 
 3.7.5 All financial reports under this Section 3.7 will be certified by the chief financial officer of Licensee or
Licensee’s qualified financial representative. 
 3.7.6 Licensee shall maintain and require its Affiliates and all Sublicensees to
maintain, complete and accurate books and records which enable the royalties, fees, and payments payable under this Agreement to be verified. The records must be maintained for [*] after the submission of each report under Article 3. Upon reasonable
prior written notice to Licensee, Licensee and its Affiliates and all Sublicensees will provide Licensor and/or the REGENXBIO Licensors (and their respective accountants) with access to all of the relevant books, records, and related background
information required to conduct a review or audit of the royalties, fees, and payments payable to Licensor under this Agreement to be verified. Access will be made available: (a) during normal business hours; (b) in a manner reasonably
designed to facilitate the auditing party’s review or audit without unreasonable disruption to Licensee’s business; and (c) no more than once each calendar year during the term of this Agreement and for a period of [*] thereafter.
Licensee will promptly pay to Licensor the amount of any underpayment determined by the review or audit, plus accrued interest. If the review or audit determines that Licensee has underpaid any payment by [*] or more, then Licensee will also
promptly pay the costs and expenses of Licensor and the REGENXBIO Licensors and their respective accountants in connection with the review or audit. If the review or audit determines that Licensee has overpaid any payment, then Licensor shall refund
the overpayment to Licensee. 
 3.8 Currency, Interest. 

3.8.1 All dollar amounts referred to in this Agreement are expressed in United States dollars. All payments to Licensor under this Agreement
must be made in United States dollars. 
 3.8.2 If Licensee receives payment in a currency other than United States dollars for which a
royalty or fee or other payment is owed under this Agreement, then (a) the payment will be converted into United States dollars at the conversion rate for the foreign currency as published in the eastern edition of the Wall Street Journal, N.Y.
edition, as of the last business day of the Calendar Quarter in which the payment was received by Licensee; and (b) the conversion computation will be documented by Licensee in the applicable report delivered to Licensor under Section 3.7. 

3.8.3 All amounts that are not paid by Licensee when due will accrue interest from the date due until paid at a rate equal to 1.5% per
month (or the maximum allowed by law, if less). 

  

					
		  	17	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

3.9 Taxes and Withholding. 
 3.9.1 All
payments hereunder will be made free and clear of, and without deduction or deferment in respect of, and Licensee shall pay and be responsible for, and shall hold Licensor harmless from and against, any taxes, duties, levies, fees, or charges,
including sales, use, transfer, excise, import, and value added taxes (including any interest, penalties, or additional amounts imposed with respect thereto) but excluding withholding taxes to the extent provided in Section 3.9.2. At the
request of Licensee, Licensor will give Licensee such reasonable assistance, which will include the provision of documentation as may be required by the relevant tax authority, to enable Licensee to pay and report and, as applicable, claim exemption
from or reduction of, such tax, duty, levy, fee, or charge. 
 3.9.2 If any payment made by Licensee hereunder becomes subject to withholding
taxes with respect to Licensor’s gross or net income under the laws of any jurisdiction, Licensee will deduct and withhold the amount of such taxes for the account of Licensor to the extent required by law and will pay the amounts of such taxes
to the proper governmental authority in a timely manner and promptly transmit to Licensor appropriate proof of payment of such withholding taxes. At the request of Licensor, Licensee will give Licensor such reasonable assistance, which will include
the provision of appropriate certificates of such deductions made together with other supporting documentation as may be required by the relevant tax authority, to enable Licensor to claim exemption from or reduction of, or otherwise obtain
repayment of, such withholding taxes, and will upon request provide such additional documentation from time to time as is reasonably required to confirm the payment of withholding tax. 

ARTICLE 4: DILIGENCE 
 4.1 Diligence
Obligations. 
 4.1.1 Licensed Product Diligence Obligations. Licensee will use commercially reasonable efforts to develop,
commercialize, market, promote, and sell Licensed Products in the CPVT Field unless Licensee elects a Substitution Indication Option for the CPVT Field. Furthermore, if Licensee exercises the Substitution Indication Option and/or Additional
Indication Option granted to Licensee under Sections 2.2 and 2.3, respectively, Licensee will use commercially reasonable efforts to develop, commercialize, market, promote, and sell Licensed Products for the Disease Indication(s) subject to such
option in the Commercial Field. Commercially reasonable efforts means efforts equivalent to those utilized by [*]. Without limiting the foregoing, Licensee will meet the following: 

 

	 	(a)	     

 (i) acceptance by the FDA of an Investigational New Drug
application, or acceptance by the European Medicines Agency (or any successor entity thereto) of an equivalent application, for a Licensed Product in the CPVT Field by no later than [*] after the Effective Date; or 

  

					
		  	18	  	 *Confidential Treatment Requested.

 CONFIDENTIAL 
  

(ii) if Licensee exercises the Substitution Indication Option granted to Licensee under Section 2.2, acceptance by the FDA of an
Investigational New Drug application, or acceptance by the European Medicines Agency 
 (or any successor entity thereto) of an equivalent
application, for a Licensed Product for an Additional Disease Indication selected in the exercise of such Substitution Indication Option by no later than [*] after the Substitution Grant Date; and 

 

	 	(b)	if Licensee exercises the Additional Indication Option granted to Licensee under Section 2.3, acceptance by the FDA of an Investigational New Drug application, or acceptance by the European Medicines Agency (or any
successor entity thereto) of an equivalent application, for a Licensed Product for an Additional Disease Indication selected in the exercise of such Additional Indication Option by no later than [*] after the Grant Date; 

provided, however, that, if Licensee expects not to achieve one of the milestones set forth in clause (a) or (b) on or before the
specified deadline in such clause (a) or (b), Licensee may pay Licensor an extension fee of [*] for a [*] extension of the deadline in clause (a), and independently, Licensee may pay Licensor an extension of [*] for a [*] extension of the
deadline in clause (b). Licensee is only entitled to [*] for the milestone in (a) and [*] for the milestone in (b). Licensee will provide Licensor written notice within [*] of achieving each milestone set forth in clause (a) and (b). 

4.2 Development Plans. 
 4.2.1 For each
Disease Indication and corresponding Licensed Product in the Commercial Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plan for the Licensed
Product in the CPVT Field will be delivered within [*] after the Effective Date, and the Development Plan for each Additional Disease Indication licensed in accordance with Section 2.2 or Section 2.3 will be delivered within [*] of the
date on which the applicable indication is added to the Commercial Field. 
 4.2.2 Each Development Plan will cover the next two
(2) years, and will include future development activities to be undertaken by Licensee, its Affiliates, or any Sublicensees during the next reporting period under Section 4.3 relating directly to the Licensed Product, Licensee’s
strategy to bring the Licensed Product to commercialization, and projected timeline for completing the necessary tasks to accomplish the goals of the strategy. 

4.2.3 Following receipt by Licensor of each Development Plan, Licensor will promptly notify Licensee of any comments or requested revisions,
and the Parties will thereupon negotiate any appropriate revisions in good faith. With respect to development milestones to be set forth in the initial Development Plans for CVPT Field, the Parties will agree upon reasonable milestones and
completion dates to be set forth in the Development Plan (and any amendments thereto). 

  

					
		  	19	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

4.3 Reporting. Within [*] after the Effective Date and within [*] of each December 1 thereafter, Licensee shall provide Licensor with written
progress reports, setting forth in such detail as Licensor may reasonably request, the progress of the development, evaluation, testing, and commercialization of each Licensed Product. Licensee will also notify Licensor within [*] of the first
commercial sale by Licensee, its Affiliates, or any Sublicensees of each Licensed Product. Such a report (“Development Progress Report”), setting forth the current stage of development of Licensed Products, shall include: 

4.3.1 Date of Development Progress Report and time covered by such report; 

4.3.2 Major activities and accomplishments completed by Licensee, its Affiliates, and any Sublicensees relating directly to the Licensed
Product since the last Development Progress Report; 
 4.3.3 Significant research and development projects relating directly to the Licensed
Product currently being performed by Licensee, its Affiliates, and any Sublicensees and good faith, but non-binding, projected dates of completion; 

4.3.4 A Development Plan covering the next two (2) years at least, which will include future development activities to be undertaken by
Licensee, its Affiliates, or any Sublicensees during the next reporting period relating directly to the Licensed Product, Licensee’s strategy to bring the Licensed Product to commercialization, and good faith, but non-binding, projected
timeline for completing the necessary tasks to accomplish the goals of the strategy; 
 4.3.5 Projected total development remaining before
product launch of each Licensed Product; and 
 4.3.6 Summary of significant development efforts using the Licensed Patents being performed
by Third Parties, including the nature of the relationship between Licensee and such Third Parties. 
 4.4 Confidential Information. The Parties agree
that Development Progress Reports shall be deemed Licensee’s Confidential Information; provided that Licensor may share a copy of such reports with the REGENX Licensors under confidentiality. 

4.5 Improvements. Simultaneously with the Development Progress Report, Licensee shall deliver a detailed description of any Licensee Inventions and any
Licensed Back Improvements, if not previously provided pursuant to Section 2.8.3, which shall be Licensee’s Confidential Information. 

ARTICLE 5: CONFIDENTIALITY 
 5.1
Treatment of Confidential Information. Each Party, as a receiving party (a “Receiving Party”), agrees that it will (a) treat Confidential Information of the other Party (the “Disclosing Party”) as
strictly confidential; (b) protect the Confidential Information of the Disclosing Party with at least the same degree of care as it protects its own confidential and proprietary information, and in any event with not less than a reasonable
degree of care; (c) not disclose such Confidential Information to Third Parties without the prior written consent of the Disclosing Party, except as may be permitted in this Agreement; provided that any disclosure permitted hereunder shall be
under confidentiality agreements with provisions at least as stringent as those contained in this Agreement; and (d) not use such Confidential Information for purposes other 

  

					
		  	20	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

than those authorized expressly in this Agreement. The Receiving Party agrees to ensure that its employees who have access to Confidential Information are
obligated in writing to abide by confidentiality obligations at least as stringent as those contained under this Agreement. 
 5.2 Public
Announcements. 
 5.2.1 The Parties agree they will release a joint press release in the form attached hereto as Exhibit B. Except
as provided in Section 5.2.2, any other press releases by either Party with respect to the other Party or any other public disclosures concerning the existence of or terms of this Agreement shall be subject to review and approval by the other
Party. Once the joint press release or any other written statement is approved for disclosure by both Parties, either Party may make subsequent public disclosure of the contents of such statement without the further approval of the other Party. 

5.2.2 Notwithstanding Section 5.2.1, Licensor has the right to publish (through press releases, scientific journals, or otherwise) and
refer to any clinical, regulatory, or research results related to Licensee’s Licensed Product or AAV9 program that have been publicly disclosed by Licensee, including referring to Licensee by name as a licensee of Licensor, which publication or
referral by Licensor shall not require the prior consent of Licensee. 
 5.3 Authorized Disclosure. Notwithstanding the provisions of Section 5.1
or 5.2, either Party may disclose the other’s Confidential Information or make such a disclosure of the existence of and/or terms of this Agreement to any [*]; provided that, in each case, such recipient of Confidential Information is obligated
to keep such information confidential on terms no less stringent than those set forth in this Agreement. Furthermore, Licensee agrees that Licensor may share a copy of this Agreement, reports and notices provided by Licensee to Licensor pursuant to
the terms of this Agreement, and copies of sublicense agreements provided to Licensor hereunder with the REGENXBIO Licensors to the extent required by the GSK Agreement and the Penn Agreement, under confidentiality. In the event that the Receiving
Party receives service of legal process that purports to compel disclosure of the Disclosing Party’s Confidential Information or becomes obligated by law, rule, regulation or rules of a security exchange, to disclose the Confidential
Information of the Disclosing Party or the existence of or terms of this Agreement to any governmental authority, then, to the extent legally permitted, the Receiving Party shall promptly notify the Disclosing Party, so that the Disclosing Party may
seek an appropriate protective order or other remedy with respect to narrowing the scope of such requirement and/or waive compliance by the Receiving Party with the provisions of this Agreement. The Receiving Party will, at the Disclosing
Party’s request and expense, provide the Disclosing Party with reasonable assistance in obtaining such protective order or other remedy. If, in the absence of such protective order or other remedy, the Receiving Party is nonetheless required by
law, rule, regulation or rules of a security exchange, to disclose the existence of or terms of this Agreement or other Confidential Information of the Disclosing Party, the Receiving Party may disclose such Confidential Information without
liability hereunder; provided that the Receiving Party shall furnish only such portion of the Confidential Information that is legally required to be disclosed and only to the extent required by law. 

5.4 Term of Confidentiality. The obligations of this Article 5 shall continue for a period of [*] following the expiration or termination of this
Agreement. 

  

					
		  	21	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

ARTICLE 6: TERM AND TERMINATION 
 6.1
Term of Agreement. This Agreement will commence on the Effective Date and continue in effect on a country-by-country, Licensed Product-by-Licensed Product basis until the later of the expiration, lapse, abandonment, or invalidation of the
last Valid Claim of the Licensed Patents to expire, lapse, become abandoned, become unenforceable for the applicable Licensed Product; or (ii) 10 years from the first commercial sale, unless sooner terminated as provided in this Agreement. 

6.2 Termination for Failure to Exercise Option. This Agreement will terminate automatically with respect to any unexercised Additional Disease
Indications at the end of the Substitution Indication Term and Additional Indication Term. 
 6.3 Term and Additional Indication Term for purposes of the
Substitution Indication Option. This Agreement will terminate automatically with respect to the license granted in Section 2.1, if Licensee has exercised the Substitution Indication Option in accordance with Section 2.2. 

6.4 Licensee’s Right to Terminate. Licensee may, upon [*] prior written notice to Licensor, terminate this Agreement for any reason, with or
without cause. In exercising such termination right, Licensee may terminate the Agreement in its entirety or, if desired, Licensee may specify in the written notice that this Agreement is terminating only with respect to one or more of the Disease
Indications within the Commercial Field. 
 6.5 Termination for Breach. 

6.5.1 Licensor may terminate this Agreement, if Licensee is late in paying to Licensor royalties, fees, or any other monies due under this
Agreement, and Licensee does not pay Licensor in full within 15 days upon written demand from Licensor, which termination shall be effective immediately upon the expiration of such 15-day cure period. 

6.5.2 Either Party may terminate this Agreement, if the other Party materially breaches this Agreement and does not cure such material breach
within 30 days after written notice of the breach, which termination shall be effective immediately upon the expiration of such 30-day cure period. Notwithstanding the above, if Licensee disputes in good faith that such material breach exists, and
gives Licensor written notice of such dispute within 30 days following Licensee’s receipt of Licensor’s notice of default, then, Licensor may not terminate this Agreement until the dispute is resolved in accordance with Section 10.6;
provided that Licensor shall be entitled to terminate this Agreement at the end of the original 30-day cure period, without waiting for resolution of the dispute in accordance with Section 10.6, if the breach by Licensee of this Agreement would
cause Licensor to be in breach of the GSK Agreement or the Penn Agreement. 
 6.6 Termination for Insolvency. Licensor shall have the right to
terminate this Agreement, upon notice to the Licensee, in the event that: (a) Licensee shall have: (i) voluntarily commenced any proceeding or filed any petition seeking relief under the bankruptcy, insolvency or other similar laws of any
jurisdiction, (ii) applied for, or consented to, the appointment of a receiver, trustee, custodian, sequestrator, conciliator, administrator or similar official for it or for all or substantially all of its property, (iii) filed an answer
admitting the material allegations of a petition filed against or in respect of it in any such proceeding, (iv) made a general assignment 

  

					
		  	22	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

for the benefit of creditors of all or substantially all of its assets, (v) admitted in writing its inability to pay all or substantially all of its debts
as they become due, or (vi) taken corporate action for the purpose of effecting any of the foregoing; or (b) An involuntary proceeding shall have been commenced, or any involuntary petition shall have been filed, in a court of competent
jurisdiction seeking: (i) relief in respect of Licensee, or of its property, under the bankruptcy, insolvency or similar laws of any jurisdiction, (ii) the appointment of a receiver, trustee, custodian, sequestrator, conciliator,
administrator or similar official for the Licensee or for all or substantially all of its property, or (iii) the winding-up or liquidation of the Licensee; and, in each case, such proceeding or petition shall have continued undismissed for
sixty (60) days, or an order or decree approving or ordering any of the foregoing shall have continued unstayed, unappealed and in effect for thirty (30) days. 

6.7 Patent Challenge. 
 6.7.1 Licensor may
terminate this Agreement, effective immediately upon written notice to Licensee, upon the commencement by Licensee or any of its Affiliates of a Patent Challenge. 

6.7.2 Licensee shall include in each sublicense agreement entered into with a Sublicensee a right of Licensee to terminate such sublicense
agreement if such Sublicensee commences a Patent Challenge; and Licensee shall terminate the sublicense agreement, effective immediately upon written notice to the Sublicensee, if the Sublicensee commences a Patent Challenge. If Sublicensee
commences a Patent Challenge and Licensee fails to terminate the applicable sublicense agreement, then Licensor may terminate such sublicense agreement, effective immediately upon written notice to Sublicense. 

6.7.3 For purposes of this Section 6.7, “Patent Challenge” means any action against Licensor or the REGENXBIO Licensors,
including an action for declaratory judgment, to declare or render invalid or unenforceable the Licensed Patents, or any claim thereof. 
 6.8 Effects of
Termination. The effect of termination pursuant to Section 6.3, by Licensee pursuant to Section 6.4, by either Party, as applicable, under Section 6.5, or by Licensor pursuant to Section 6.6 or Section 6.7 shall be as
follows; provided that for any termination with respect to a particular Disease Indication, then the following provisions shall apply only with respect to such Disease Indication: 

6.8.1 The licenses granted by Licensor hereunder shall terminate, and Licensee, its Affiliates, and (unless the sublicense agreement is
assigned pursuant to Section 6.8.2) all Sublicensees shall cease to make, have made, use, import, sell, and offer for sale all Licensed Products and shall cease to otherwise practice the Licensed Patents; provided that Licensee and its
Sublicensees shall have the right to continue to sell its existing inventories of Licensed Products for a period not to exceed [*] after the effective date of such termination; 

6.8.2 If termination is by Licensor pursuant to Section 6.5, 6.6 or 6.7, then, at Licensor’s request, Licensee shall assign to
Licensor, and Licensor shall assume, any or all sublicenses granted to Third Parties to the extent of the rights licensed to Licensee hereunder and sublicensed to the Sublicensee unless the Sublicensee notifies Licensor in writing that the 

  

					
		  	23	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

Sublicensee does not wish such sublicense to be so assigned (in which case such sublicense shall terminate); provided that (i) prior to such assignment,
Licensee shall advise Licensor whether such Sublicensee is then in full compliance with all terms and conditions of its sublicense and continues to perform thereunder, and, if such Sublicensee is not in full compliance or is not continuing to
perform, Licensor may elect not to have such sublicense assigned; and (ii) following such assignment, Licensor shall not be liable to such Sublicensee with respect to any obligations of Licensee to the Sublicensee that are not consistent with,
or not required by, Licensor’s obligations to Licensee under this Agreement; if termination is for any other reason, then all sublicenses shall terminate; 

6.8.3 If termination is by Licensee pursuant to Section 6.4 or by Licensor pursuant to Section 6.5, 6.6, or 6.7, Licensee shall
grant, and hereby grants, to Licensor a non-exclusive, perpetual, irrevocable, worldwide, royalty-free, transferable, sublicensable license under any Licensed Back Improvements for the research, development, and commercialization of products in any
therapeutic indication; 
 6.8.4 Licensee shall pay all monies then-owed to Licensor under this Agreement; and 

6.8.5 Each Receiving Party shall, at the Disclosing Party’s request, return all Confidential Information of the Disclosing Party.
Notwithstanding the foregoing, one copy may be kept by either Party for a record of that Party’s obligations. 
 6.8.6 If termination is
only with respect to a particular Disease Indication within the Commercial Field, but not all Disease Indications, then the provisions of this Section 6.8 shall only apply with respect to the terminated Disease Indications, and this Agreement
shall continue with respect to the non-terminated Disease Indications. 
 6.9 Survival. Licensee’s obligation to pay all monies due and owed to
Licensor under this Agreement which have matured as of the effective date of termination or expiration shall survive the termination or expiration of this Agreement. In addition, the provisions of Section 2.4, (Retained Rights),
Section 2.5 (Government Rights), Section 2.7 (Non-Exclusive License Under Licensee Inventions), Section 2.8 (Improvements) Article 3 (Consideration) (with respect to any final reports or to the extent any amounts are due but unpaid),
Section 3.7 (Reports and Records), Section 4.4 (Confidential Information), Article 5 (Confidentiality), Article 6 (Term and Termination), Section 8.3 (Disclaimer of Warranties, Damages), Section 8.4 (Indemnification),
Section 8.5 (Insurance), Article 9 (Use of Name), and Article 10 (Additional Provisions) shall survive such termination or expiration of this Agreement in accordance with their respective terms. 

ARTICLE 7: PATENT MAINTENANCE; PATENT INFRINGEMENT 

7.1 Prosecution of Licensed Patents. As between Licensor and Licensee, the Parties agree as follows: 

7.1.1 Licensor shall have the sole right, but not the obligation, to Prosecute patent applications and issued patents within Licensed Patents,
in Licensor’s sole discretion. Subject to Section 7.1.3, Licensor shall provide Licensee with a reasonable opportunity to review and provide comments in connection with the Prosecution of the Licensed Patents; and Licensor shall keep
Licensee reasonably informed as to all material developments with respect to such Licensed Patents and shall supply to Licensee copies of material communications received and filed in connection with the Prosecution of such Licensed Patents. 

  
 24 

 CONFIDENTIAL 
  

7.1.2 Nothing in this Agreement obligates Licensor to continue to Prosecute any patent applications or issued patents, and Licensee
acknowledges that Licensor shall have no obligation to undertake any inter-party proceedings, such as oppositions, inter partes review, or interferences, or to undertake any re-examination or re-issue proceedings, in either case, with respect
to the Licensed Patents. 
 7.1.3 Licensee acknowledges that The Trustees of the University of Pennsylvania control Prosecution of the
Licensed Patents, with Licensor having certain rights to review. Licensee acknowledges and agrees that (a) the rights and obligations under this Section 7.1 are subject to the rights of the REGENXBIO Licensors set forth in the GSK
Agreement and Penn Agreement with respect to the Licensed Patents, and (b) Licensor’s obligations under this Agreement only apply to the extent of Licensor’s rights with respect to participation in Prosecuting the Licensed Patents
under the GSK Agreement and the Penn Agreement. 
 7.2 Infringement Actions Against Third Parties. 

7.2.1 Licensee is responsible for notifying the Licensor promptly of any infringement of Licensed Patents (other than Retained Rights) that may
come to Licensee’s attention, including any “patent certification” filed in the United States under 21 U.S.C. § 355(b)(2) or 21 U.S.C. § 355(j)(2) or similar provisions in other jurisdictions alleging the invalidity,
unenforceability or non-infringement of any Licensed Patents, and any notification received pursuant to subsection (k) of 42 U.S.C § 262 for any Licensed Product that becomes a “reference product.” 

7.2.2 As between Licensor and Licensee, but subject to any obligations of Licensor to the REGENXBIO Licensors, Licensor shall have the sole
right, but not the obligation, to prosecute any such infringement at its own expense and [*] in connection therewith that are unrelated to the manufacture, use or sale of Licensed Products, with damages recovered in connection with any infringement
related to the manufacture, use or sale of Licensed Products shall be [*]. In any action to enforce any of the Licensed Patents, Licensee, at the request and expense of Licensor, shall cooperate to the fullest extent reasonably possible, including
in the event that, if Licensor is unable to initiate or prosecute such action solely in its own name, Licensee shall join such action voluntarily and shall execute all documents necessary to initiate litigation to prosecute, maintain, and settle
such action. Nothing in this Agreement obligates Licensor to bring or prosecute lawsuits against Third Parties for infringement of any Licensed Patents. 

7.2.3 Licensee shall have no right to undertake prosecution of any such infringement. 

7.3 Defense of Infringement Claims. In the event Licensee or Licensor becomes aware that Licensee’s or any of its Affiliates’ or any
Sublicensees’ practice of the Licensed Patents is the subject of a claim for patent infringement by a Third Party, that Party shall promptly notify the other, and the Parties shall consider the claim and the most appropriate action to take.
Licensee 
  

  

					
		  	25	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

shall cause each of its Affiliates and each Sublicensee to notify Licensee promptly in the event such entity becomes aware that its practice of the Licensed
Patents is the subject of a claim of patent infringement by another. To the extent Licensor takes any action, Licensor (or the REGENXBIO Licensors) shall have the right to require Licensee’s reasonable cooperation in any such suit, upon written
notice to Licensee; and Licensee shall have the obligation to participate upon Licensor’s request, in which event, Licensor shall bear the cost of Licensee’s participation. Without Licensor’s prior written permission, Licensee must
not settle or compromise any such suit in a manner that imposes any material obligations or restrictions on Licensor or the REGENXBIO Licensors or grants any rights to the Licensed Patents other than rights that Licensee has the right to grant under
this Agreement. 
 ARTICLE 8: WARRANTIES; INDEMNIFICATION 

8.1 Representations and Warranties by Licensor. Licensor represents and warrants to Licensee as of the Effective Date: 

8.1.1 Licensor has the right, power, and authority to enter into this Agreement and to grant to Licensee the rights specified in this
Agreement; 
 8.1.2 This Agreement when executed shall become the legal, valid, and binding obligation of it, enforceable against it, in
accordance with its terms; 
 8.1.3 There are no actions, suits, proceedings, or arbitrations pending or, to Licensor’s knowledge,
threatened against Licensor relating to the Licensed Patents that would be inconsistent with the rights granted to Licensee under this Agreement; 

8.1.4 To Licensor’s knowledge, (a) the Licensed Patents are solely owned by The Trustees of the University of Pennsylvania, and
(b) no Third Party (other than the REGENXBIO Licensors) has any right, interest, or claim in or to such Licensed Patents in the Commercial Field that are inconsistent with those granted to Licensee in the Commercial Field under this Agreement;

 8.1.5 To Licensor’s knowledge, Licensor does not Control as of the Effective Date any patent or patent application (other than the
Licensed Patents (as defined in Section 1.17) that would necessarily be infringed by the use or sale of AAV9 in the CPVT Field. If it is determined, in accordance with the procedure of this Section 8.1.5, that Licensor Controls as of the
Effective Date a patent or patent application (other than the Licensed Patents) that would necessarily be infringed by the use or sale of AAV9 in the CPVT Field, then Licensee’s sole remedy shall be the inclusion of the applicable patent or
patent application as a “Licensed Patent” hereunder but solely to the extent of the claim(s) that would necessarily be infringed by the use or sale of AAV9. At any time during the term of this Agreement, Licensee may notify Licensor in
writing of any such patent or patent application that Licensee believes should be included as a “Licensed Patent” pursuant to this Section 8.1.5. Such written notice shall identify the relevant patent or patent application and
relevant claim(s) and shall explain briefly why Licensee, in good faith, believes it should be included as a “Licensed Patent.” Licensor has [*] following Licensor’s receipt of Licensee’s written notice to dispute the inclusion
of such patent or patent application or the scope of the remedy; in which event, such dispute will be resolved in 
  

  

					
		  	26	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

accordance with Section 10.6. Upon the Parties’ agreement (or a resolution, in favor of Licensee, of the dispute pursuant to Section 10.6), the applicable
claim(s) of the applicable patent or patent application will be deemed a “Licensed Patent” hereunder. For the avoidance of doubt, Licensor makes no representation or warranty under this Section 8.1.5 as to any claim of a patent or patent
application covering the manufacture of AAV9, and Licensee acknowledges that manufacturing claims of any patents or patent applications will not be added as “Licensed Patents” pursuant to the procedure set forth in this Section 8.1.5. For
the purpose of this Section 8.1.5, “Control” means the possession by Licensor (whether by ownership or license, other than pursuant to this Agreement) of the ability to grant to Licensee access, a license, or a sublicense (as applicable)
to the applicable patent or patent application on the terms and conditions set forth herein without violating the terms of any agreement or other arrangement with any Third Party; and 

8.1.6 Licensor has not received any written notice from any Third Party patentee alleging such Third Party’s patents by the practice of
the Licensed Patents in the CPVT Field. 
 8.2 Representations and Warranties by Licensee. Licensee represents and warrants to Licensor as of the
Effective Date that: 
 8.2.1 Licensee has the right, power, and authority to enter into this Agreement and to grant the rights granted by it
hereunder; 
 8.2.2 This Agreement when executed shall become the legal, valid, and binding obligation of it, enforceable against it, in
accordance with its terms; 
 8.2.3 Licensee has the ability and the resources, including financial resources, necessary to carry out its
obligations under this Agreement; and 
 8.2.4 There are no actions, suits, proceedings, or arbitrations pending or, to Licensee’s
knowledge, threatened against Licensee that would impact activities under this Agreement. 
 8.3 Disclaimer of Warranties, Damages. EXCEPT AS SET
FORTH IN SECTION 8.1, THE LICENSED PATENTS, LICENSED PRODUCTS, AND ALL RIGHTS LICENSED UNDER THIS AGREEMENT ARE PROVIDED ON AN “AS IS” BASIS, AND LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED, WITH RESPECT THERETO. BY
WAY OF EXAMPLE BUT NOT OF LIMITATION, EXCEPT AS SET FORTH IN SECTION 8.1, LICENSOR MAKES NO REPRESENTATIONS OR WARRANTIES, AND HEREBY DISCLAIMS ALL EXPRESS AND IMPLIED REPRESENTATIONS AND WARRANTIES, (i) OF COMMERCIAL UTILITY, ACCURACY,
COMPLETENESS, PERFORMANCE, TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, VALIDITY OR ENFORCEABILITY OF THE LICENSED PATENTS, AND PROFITABILITY; OR (ii) THAT THE USE OF THE LICENSED PATENTS OR LICENSED PRODUCTS WILL NOT INFRINGE ANY
PATENT, COPYRIGHT, TRADEMARK, OR OTHER PROPRIETARY RIGHTS OF THIRD PARTIES. EXCEPT AS SET FORTH HEREIN, NONE OF LICENSOR AND THE REGENXBIO LICENSORS SHALL BE LIABLE TO LICENSEE, LICENSEE’S SUCCESSORS OR ASSIGNS, ANY SUBLICENSEES, OR ANY THIRD
PARTY WITH RESPECT TO: (a) ANY CLAIM 

  
 27 

 CONFIDENTIAL 
  

ARISING FROM USE OF THE LICENSED PATENTS, LICENSED PRODUCTS, AND ANY OR ALL RIGHTS LICENSED UNDER THIS AGREEMENT OR FROM THE DEVELOPMENT, TESTING, MANUFACTURE,
USE, OR SALE OF LICENSED PRODUCTS; OR (b) ANY CLAIM FOR LOSS OF PROFITS, LOSS OR INTERRUPTION OF BUSINESS, OR FOR INDIRECT, SPECIAL, INCIDENTAL, EXEMPLARY, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND, INCLUDING ANY ARISING FROM OR RELATING
TO ANY BREACH OF THIS AGREEMENT OR THE EXERCISE OF RIGHTS HEREUNDER, REGARDLESS OF ANY NOTICE OF SUCH DAMAGES. NOTHING IN THIS SECTION 8.3 IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF EITHER PARTY UNDER SECTION 8.4
OR TO LIMIT A PARTY’S LIABILITY FOR BREACHES OF ITS OBLIGATION REGARDING CONFIDENTIALITY UNDER Article 5. 
 8.4 Indemnification. 

8.4.1 By Licensee. Licensee shall defend, indemnify, and hold harmless Licensor, the REGENXBIO Licensors, and their respective
shareholders, members, officers, trustees, faculty, students, contractors, agents, and employees (individually, a “Licensor Indemnified Party” and, collectively, the “Licensor Indemnified Parties”) from and against
any and all Third Party liability, loss, damage, action, claim, fee, cost, or expense (including attorneys’ fees) (individually, a “Third Party Liability” and, collectively, the “Third Party Liabilities”)
suffered or incurred by the Licensor Indemnified Parties from claims of such Third Parties that result from or arise out of: [*]; provided, however, that Licensee shall not be liable for claims to the extent based on any breach by Licensor of the
representations, warranties, or obligations of this Agreement or the gross negligence or intentional misconduct of any of the Licensor Indemnified Parties. Without limiting the foregoing, Licensee must defend, indemnify, and hold harmless the
Licensor Indemnified Parties from and against any Third Party Liabilities resulting from: 
  

	 	(a)	any [*] or other claim of any kind related to the [*] by a Third Party of a Licensed Product that was [*] by Licensee, its Affiliates, any Sublicensees, their respective assignees, or vendors; 

 

	 	(b)	any claim by a Third Party that [*]; and 

  

	 	(c)	[*] conducted by or on behalf of Licensee, its Affiliates, any Sublicensees, their respective assignees, or vendors relating to the Licensed Patents or Licensed Products, including any claim by or [*].

 8.4.2 By Licensor. Licensor shall defend, indemnify, and hold harmless Licensee, its shareholders, members, officers,
contractors, agents, and employees (individually, a “Licensee Indemnified Party” and, collectively, the “Licensee Indemnified Parties”) from and against any and all Third Party Liabilities suffered or incurred by the Licensee
Indemnified Parties from claims of such Third Parties that results from or arises out of: [*]; provided, however, that Licensor shall not be liable for claims based on any breach by Licensee of the representations, warranties, or obligations of this
Agreement or the gross negligence or intentional misconduct of any of the Licensee Indemnified Parties. 
  

  

					
		  	28	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

8.4.3 Indemnification Procedure. Each Party, as an indemnifying party (an “Indemnifying Party”), shall not be permitted
to settle or compromise any claim or action giving rise to Third Party Liabilities in a manner that imposes any restrictions or obligations on any indemnified party (an “Indemnified Party”) without the other Party’s prior
written consent or, if Licensee is the Indemnifying Party, that grants any rights to the Licensed Patents or Licensed Products other than those Licensee has the right to grant under this Agreement without Licensor’s prior written consent. The
Indemnifying Party shall be permitted to control any litigation or potential litigation involving the defense of any claim subject to indemnification pursuant to this Section 8.4, including the selection of counsel, with the reasonable approval
of the Indemnified Party. Upon the Indemnifying Party’s reasonable request, the Indemnified Parties will reasonably cooperate with the Indemnifying Party in the defense and settlement of any such claim, at the Indemnifying Party’s cost and
expense. If an Indemnifying Party fails or declines to assume the defense of any such claim or action within [*] after notice thereof, the Indemnified Party may assume the defense of such claim or action at the cost and risk of the Indemnifying
Party, and any Third Party Liabilities related thereto shall be conclusively deemed a Third Party Liability of the Indemnifying Party. The indemnification rights of a Indemnified Party contained in this Agreement are in addition to all other rights
that such Indemnified Party may have at law or in equity or otherwise. The Indemnifying Party will pay directly all Third Party Liabilities incurred for defense or negotiation of any claim hereunder or will reimburse the Indemnified Party for all
documented Third Party Liabilities incident to the defense or negotiation of any such claim within [*] after the Indemnifying Party’s receipt of invoices for such fees, expenses, and charges. 

8.5 Insurance. Licensee will procure and maintain insurance policies for the following coverages with respect to product liability, personal injury,
bodily injury, and property damage arising out of Licensee’s (and its Affiliates’ and any Sublicensees’) performance under this Agreement: (a) during the term of this Agreement, comprehensive general liability, including broad
form and contractual liability, in a minimum amount of [*] combined single limit per occurrence (or claim) and in the aggregate annually; (b) prior to the commencement of clinical trials involving Licensed Products and thereafter for a period
of not less than [*] (or such longer period as Licensee is required by applicable law to continue to monitor the participants in the clinical trial), clinical trials coverage in amounts that are reasonable and customary in the U.S. pharmaceutical
industry, subject always to a minimum limit of [*] combined single limit per occurrence (or claim) and in the aggregate annually; and (c) from prior to the first commercial sale of a Licensed Product until [*] after the last sale of a Licensed
Product, product liability coverage, in amounts that are reasonable and customary in the U.S. pharmaceutical industry, subject always to a minimum limit of [*] combined single limit per occurrence (or claim) and in the aggregate annually. Licensor
may review periodically the adequacy of the minimum amounts of insurance for each coverage required by this Section 8.5, and Licensor reserves the right to require Licensee to adjust the limits accordingly. The required minimum amounts of
insurance do not constitute a limitation on Licensee’s liability or indemnification obligations to the Licensor Indemnified Parties under this Agreement. The policies of insurance required by this Section 8.5 will be issued by an insurance
carrier with an A.M. best rating of [*] or better and will name Licensor as an additional insured with respect to Licensee’s performance (and its Affiliates’ and any Sublicensees’) under this Agreement. Licensee will provide Licensor
with insurance certificates evidencing the required coverage within [*] after the Effective Date and the commencement of each policy period and any renewal periods. Each certificate will provide that the insurance carrier will notify Licensor in
writing at least [*] prior to the cancellation or material change in coverage. Licensee will cause all Sublicensees to comply with the terms of this Section 8.5 to the same extent as Licensee. 

  

					
		  	29	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

ARTICLE 9: USE OF NAME 
 9.1 Licensee, its
Affiliates, any Sublicensees, and all of its and their employees and agents must not use Licensor’s, the University of Pennsylvania’s, or SmithKline Beecham Corporation’s name, seal, logo, trademark, or service mark (or any adaptation
thereof) or the name, seal, logo, trademark, or service mark (or any adaptation thereof) of any of such entities’ representative, school, organization, employee, or student in any way without the prior written consent of Licensor or such
entity, as applicable, unless required to do so pursuant to applicable law, rule, regulation or rules of a securities exchange; provided, however that Licensee may acknowledge the existence and general nature of this Agreement, subject to
Section 5.2 or 5.3, as applicable. 
 9.2 Licensor and all of its employees and agents must not use Licensee’s name, seal, logo, trademark, or
service mark (or any adaptation thereof) in any way without the prior written consent of Licensee; provided, however that Licensor may acknowledge the existence and general nature of this Agreement, subject to Section 5.2 or 5.3, as applicable,
and refer to Licensee as a licensee of Licensor. 
 ARTICLE 10: ADDITIONAL PROVISIONS 

10.1 Relationship. Nothing in this Agreement shall be deemed to establish a relationship of principal and agent between Licensee and Licensor, nor any
of their agents or employees for any purpose whatsoever, nor shall this Agreement be construed as creating any other form of legal association or arrangement which would impose liability upon one Party for the act or failure to act of the other
Party. 
 10.2 Assignment. The rights and obligations of Licensee and Licensor hereunder shall inure to the benefit of, and shall be binding upon,
their respective permitted successors and assigns. Licensee may not assign or otherwise transfer (by operation of law or otherwise) this Agreement or any of its rights or obligations under this Agreement without the prior written consent of Licensor
which consent is in the absolute discretion of Licensor; provided, however, Licensee shall be permitted to assign or otherwise transfer (by operation of law or otherwise ) in connection with a Change of Control without the consent of Licensor so
long as Licensee: (i) requires any assignee, transferee, or successor to agree in writing to be legally bound by this Agreement to the same extent as Licensee and provides Licensor with a copy of such undertaking; (ii) provides Licensor
with written notice of the Change of Control to Licensor within 5 days of the consummation of the transaction resulting in a Change of Control of Licensee; and (iii) provides Licensor with an unredacted copy of the definitive acquisition
agreement for the Change of Control of Licensee with 5 days of the consummation of the transaction. Notwithstanding anything to the contrary in this Agreement, for clarity, in case of a Licensee Change of Control, in no event shall any intellectual
property rights owned or controlled by the acquirer or its Affiliates immediately prior to such Licensee Change of Control be included in any of the licenses granted to Licensor under this Agreement. Licensor may 

  

					
		  	30	  	

 CONFIDENTIAL 
  

assign this Agreement and its rights and obligations without the consent of Licensee. No assignment shall relieve the assigning Party of responsibility for the
performance of any accrued obligations which it has prior to such assignment. Any attempted assignment by Licensee in violation of this Section 10.2 shall be null and void and of no legal effect. 

10.3 Waiver. A waiver by either Party of a breach of any provision of this Agreement will not constitute a waiver of any subsequent breach of that
provision or a waiver of any breach of any other provision of this Agreement. 
 10.4 Notices. Notices, payments, statements, reports, and other
communications under this Agreement shall be in writing and shall be deemed to have been received as of the date received if sent by public courier (e.g., Federal Express), by Express Mail, receipt requested, by facsimile, or by electronic
mail (with a copy of such facsimile or electronic mail also sent by one of the other methods of delivery) and addressed as follows: 
  

			
	If for Licensor:	  	with a copy to:
		
	 REGENXBIO Inc.

9712 Medical Center Drive

Suite 100
 Rockville, MD
20850
 Attn: Chief Executive Officer

Telephone: 240-552-8181

Facsimile: 240-652-9692
	  	 REGENXBIO Inc.

9712 Medical Center Drive

Suite 100
 Rockville, MD
20850
 Attn: General Counsel

Telephone: 240-552-8181

Facsimile: 240-652-9692

		
	If for Licensee:	  	
		
	 Audentes Therapeutics, Inc.

101 Montgomery Street, Suite 2650

Attn: Matthew Patterson, President & CEO

Telephone: 646-712-1001

Facsimile:
 Email:
mpatterson@audentestx.com
	  	 Fenwick and West, LLP.
 1191 Second Avenue, 10th
Floor
 Seattle, WA 98101
 Attn: Effie Toshav

Telephone: 206-389-4510
 Facsimile: 206-389-4511

 Either Party may change its official address upon written notice to the other Party in accordance with this Section 10.4

 General communications required under this Agreement (including notices under Sections 2.2, 2.3, 2.6.2, 2.8.3, 3.7, 4.1, 4.2, 4.3, 7.1, 7.2, 7.3, 8.5 and
10.2 and notices of changes of address under this Section 10.4) may be sent by any of the means outlined in the first sentence of this Section 10.4 or a copy of the notice letter may be sent by electronic mail (without the requirement of a
copy being sent by another means; provided that the receiving Party has confirmed receipt of such electronic mail); however, communications related to requests for disclosures of Confidential Information, breaches or termination of this Agreement,
indemnification, and dispute resolution (including notices under Sections 5.2, 5.3, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 8.4 and 10.6) must be sent by one of the means outlined in the first sentence of this Section 10.4. 

  
 31 

 CONFIDENTIAL 
  

10.5 Applicable Law. This Agreement shall be construed and governed in accordance with the laws of the State of Delaware, without giving effect to
conflict of law provisions that may require the application of the laws of another jurisdiction. Subject to Section 10.6, the Parties hereby submit to the exclusive jurisdiction of and venue in the courts located in the State of Delaware with
respect to any and all disputes concerning the subject of this Agreement. 
 10.6 Dispute Resolution. In the event of any controversy or claim arising
out of or relating to this Agreement, the Parties shall first attempt to resolve such controversy or claim through good faith negotiations for a period of not less than [*] following notification of such controversy or claim to the other Party. If
such controversy or claim cannot be resolved by means of such negotiations during such period, then such controversy or claim shall be resolved by binding arbitration administered by the American Arbitration Association (“AAA”) in
accordance with the Commercial Arbitration Rules of the AAA in effect on the date of commencement of the arbitration, subject to the provisions of this Section 10.6. The arbitration shall be conducted as follows: 

10.6.1 The arbitration shall be conducted by three arbitrators, each of whom by training, education, or experience has knowledge of the
research, development, and commercialization of biological therapeutic products in the United States. The arbitration shall be conducted in English and held in New York, New York. 

10.6.2 In its demand for arbitration, the Party initiating the arbitration shall provide a statement setting forth the nature of the dispute,
the names and addresses of all other parties, an estimate of the amount involved (if any), the remedy sought, otherwise specifying the issue to be resolved, and appointing one neutral arbitrator. In an answering statement to be filed by the
responding Party within [*] after confirmation of the notice of filing of the demand is sent by the AAA, the responding Party shall appoint one neutral arbitrator. Within [*] from the date on which the responding Party appoints its neutral
arbitrator, the first two arbitrators shall appoint a chairperson. 
 10.6.3 If a Party fails to make the appointment of an arbitrator as
provided in Section 10.6.2, the AAA shall make the appointment. If the appointed arbitrators fail to appoint a chairperson within the time specified in Section 10.6.2 and there is no agreed extension of time, the AAA shall appoint the
chairperson. 
 10.6.4 The arbitrators will render their award in writing and, unless all Parties agree otherwise, will include an
explanation in reasonable detail of the reasons for their award. Judgment upon the award rendered by the arbitrators may be entered in any court having jurisdiction thereof, including in the courts described in Section 10.5. The arbitrators
will have the authority to grant injunctive relief and other specific performance; provided that the arbitrators will have no authority to award damages in contravention of this Agreement, and each Party irrevocably waives any claim to such damages
in contravention of this Agreement. The arbitrators will, in rendering their decision, apply the substantive law of the State of New York, without giving effect to conflict of law provisions that may require the application of the laws of another
jurisdiction. The decision and award rendered by the arbitrators will be final and non-appealable (except for an alleged act of corruption or fraud on the part of the arbitrator). 

  

					
		  	32	  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

10.6.5 The Parties shall use their reasonable efforts to conduct all dispute resolution procedures under this Agreement as expeditiously,
efficiently, and cost-effectively as possible. 
 10.6.6 All expenses and fees of the arbitrators and expenses for hearing facilities and
other expenses of the arbitration will be borne equally by the Parties unless the Parties agree otherwise or unless the arbitrators in the award assess such expenses against one of the Parties or allocate such expenses other than equally between the
Parties. Each of the Parties will bear its own counsel fees and the expenses of its witnesses except to the extent otherwise provided in this Agreement or by applicable law. 

10.6.7 Compliance with this Section 10.6 is a condition precedent to seeking relief in any court or tribunal in respect of a dispute, but
nothing in this Section 10.6 will prevent a Party from seeking equitable or other interlocutory relief in the courts of appropriate jurisdiction, pending the arbitrators’ determination of the merits of the controversy, if applicable to
protect the confidential information, property, or other rights of that Party or to otherwise prevent irreparable harm that may be caused by the other Party’s actual or threatened breach of this Agreement. 

10.7 No Discrimination. Licensee and its Affiliates, and Licensee shall require that any Sublicensees, in their respective activities under this
Agreement, shall not discriminate against any employee or applicant for employment because of race, color, sex, sexual, or affectional preference, age, religion, national, or ethnic origin, handicap, or because he or she is a disabled veteran or a
veteran (including a veteran of the Vietnam Era). 
 10.8 Compliance with Law. Licensee (and its Affiliates’ and any Sublicensees’) must
comply with all prevailing laws, rules, and regulations that apply to its activities or obligations under this Agreement. Without limiting the foregoing, it is understood that this Agreement may be subject to United States laws and regulations
controlling the export of technical data, computer software, laboratory prototypes, and other commodities, articles, and information, including the Arms Export Control Act as amended in the Export Administration Act of 1979 and that Licensee’s
obligations are contingent upon compliance with applicable United States export laws and regulations. The transfer of certain technical data and commodities may require a license from the cognizant agency of the United States Government and/or
written assurances by Licensee that Licensee shall not export data or commodities to certain foreign countries without prior approval of such agency. Licensor neither represents that a license is not required nor that, if required, it will issue.

 10.9 Entire Agreement. This Agreement embodies the entire understanding between the Parties relating to the subject matter hereof and supersedes
all prior understandings and agreements, whether written or oral. All “Confidential Information” disclosed by the Parties pursuant to such Confidential Disclosure Agreement shall be deemed “Confidential Information” under this
Agreement (unless and until it falls within one of the exclusions set forth in Section 1.9). This Agreement may not be varied except by a written document signed by duly authorized representatives of both Parties. 

  
 33 

 CONFIDENTIAL 
  

10.10 Marking. Licensee, its Affiliates, and any Sublicensees shall mark any Licensed Product (or their containers or labels) made, sold, or otherwise
distributed by it or them with any notice of patent rights necessary or desirable under applicable law to enable the Licensed Patents to be enforced to their full extent in any country where Licensed Products are made, used, sold, offered for sale,
or imported. 
 10.11 Severability and Reformation. If any provision of this Agreement is held to be invalid or unenforceable by a court of competent
jurisdiction, then such invalid or unenforceable provision will be automatically revised to be a valid or enforceable provision that comes as close as permitted by law to the Parties’ original intent; provided that, if the Parties cannot agree
upon such valid or enforceable provision, the remaining provisions of this Agreement will remain in full force and effect, unless the invalid or unenforceable provisions are of such essential importance to this Agreement that it is to be reasonably
assumed that the Parties would not have entered into this Agreement without the invalid or unenforceable provisions. 
 10.12 Further Assurances. Each
Party hereto agrees to execute, acknowledge, and deliver such further instruments, and to do all other reasonable acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 

10.13 Interpretation; Construction. The captions to the several Articles and Sections of this Agreement are included only for convenience of reference
and shall not in any way affect the construction of, or be taken into consideration in interpreting, this Agreement. In this Agreement, unless the context requires otherwise, (a) the word “including” shall be deemed to be followed by
the phrase “without limitation” or like expression; (b) references to the singular shall include the plural and vice versa; (c) references to masculine, feminine, and neuter pronouns and expressions shall be interchangeable;
(d) the words “herein” or “hereunder” relate to this Agreement; (e) “or” is disjunctive but not necessarily exclusive; (f) the word “will” shall be construed to have the same meaning and effect
as the word “shall”; (g) all references to “dollars” or “$” herein shall mean U.S. Dollars; (h) unless otherwise provided, all reference to Sections, Articles, and exhibits in this Agreement are to Sections,
Articles, and exhibits of and in this Agreement; and (i) whenever this Agreement refers to a number of days, such number shall refer to calendar days unless business days are specified. Business days shall mean a day on which banking
institutions in Washington, D.C. are open for business. Each Party represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and
applying the terms and provisions of this Agreement, the Parties agree that no presumption will apply against the Party which drafted such terms and provisions. 

10.14 Cumulative Rights and Remedies. The rights and remedies provided in this Agreement and all other rights and remedies available to either Party at
law or in equity are, to the extent permitted by law, cumulative and not exclusive of any other right or remedy now or hereafter available at law or in equity. Neither asserting a right nor employing a remedy shall preclude the concurrent assertion
of any other right or employment of any other remedy, nor shall the failure to assert any right or remedy constitute a waiver of that right or remedy. 

  
 34 

 CONFIDENTIAL 
  

10.15 Counterparts. This Agreement may be executed in one or more counterparts, each of which will be deemed an original, but all of which together will
constitute one and the same instrument. 

  
 35 

 CONFIDENTIAL 
  

IN WITNESS WHEREOF, the Parties, intending to be legally bound, have caused this License Agreement to be executed by their duly authorized
representatives. 
  

									
	REGENXBIO INC.	 		 	AUDENTES THERAPEUTICS, INC.
					
	By:	 	/s/ Kenneth T. Mills	 		 	By:	 	/s/ Matthew R. Patterson
	 Name: Kenneth T. Mills
	 		 	Name: Matthew R. Patterson
	 Title:   President & CEO
	 		 	Title:   President & CEO

  

 CONFIDENTIAL 
  

Exhibit A 
 Licensed
Patents (AAV9) 
  

									
	 Application #
	  	Patent #	 	Filing Date	 	Country	 	Status
	 [*]
	  	[*]	 	[*]	 	[*]	 	[*]

  

					
		  		  	*Confidential Treatment Requested.

 CONFIDENTIAL 
  

Exhibit B 
 Inherited
Arrhythmias 
 [*] 

  

					
		  		  	*Confidential Treatment Requested.

 Exhibit C 

Press Release 
 In process
to be agreed to by both parties

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00253-of-00352.parquet"}]]